data_6ggz_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6ggz _Structure_validation_residue.Date_analyzed 2019-01-25 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 39.3 mm . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 121.176 0.513 . . . . 0.0 110.525 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -81.75 92.96 6.72 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.756 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 75.5 p -86.4 145.62 26.79 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.11 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -83.64 52.47 2.26 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.737 0.779 . . . . 0.0 110.252 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 67.4 mttm -105.88 157.62 17.35 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.32 177.458 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . 0.527 ' HD2' ' O ' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -82.15 144.5 30.7 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.716 0.293 . . . . 0.0 110.262 177.984 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . 0.632 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.7 m -67.67 150.09 49.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.71 -177.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -96.47 72.26 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 94.97 -77.96 0.88 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.567 -177.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.3 -15.27 0.9 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 16.2 m -144.36 -177.61 5.56 Favored 'General case' 0 C--N 1.324 -0.519 0 O-C-N 122.591 -0.358 . . . . 0.0 110.131 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . 0.632 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.9 m -134.78 27.26 3.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.636 -177.439 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.31 -47.22 83.15 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.425 -178.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 18.6 t -70.61 -30.71 67.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.131 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . 0.491 ' O ' HG22 ' 1' ' 20' ' ' VAL . 95.7 t -62.71 -54.07 38.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.223 175.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.71 -28.04 68.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.128 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -64.65 -27.04 68.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.138 176.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 1.5 tmtp? -87.9 -46.28 9.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.881 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . 0.491 HG22 ' O ' ' 1' ' 16' ' ' VAL . 57.9 t -61.86 -60.36 2.83 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.898 -176.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 19.1 pt -109.06 -34.82 2.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.616 -0.265 . . . . 0.0 111.683 -176.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 135.72 -39.87 1.61 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.052 -1.071 . . . . 0.0 113.145 177.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 29.5 m -79.13 147.32 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.962 0.41 . . . . 0.0 110.865 -177.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.71 42.32 1.1 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.448 0.642 . . . . 0.0 110.318 -179.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -116.07 108.22 15.93 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.896 178.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -171.86 131.19 2.1 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.947 -177.448 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -125.93 166.17 17.41 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.846 0.355 . . . . 0.0 111.147 -173.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.44 91.93 6.05 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.964 -175.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.05 118.88 53.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.94 177.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 57.55 27.77 14.6 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.766 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.12 11.77 84.02 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.337 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . 0.556 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 10.5 mpt_? -116.19 165.8 12.75 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.061 0.458 . . . . 0.0 110.612 178.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 92.0 m -104.22 106.38 16.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.172 -176.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . 0.461 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 2.7 p -97.35 113.15 31.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.38 0.61 . . . . 0.0 110.159 174.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.9 m -85.85 145.6 27.12 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.04 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -119.77 79.66 23.84 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.086 -177.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo . . . . . 0 C--O 1.249 1.069 0 C-N-CA 122.715 2.276 . . . . 0.0 112.521 177.918 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 52.5 mt . . . . . 0 N--CA 1.456 -0.13 0 CA-C-O 120.784 0.326 . . . . 0.0 111.3 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -77.82 114.97 17.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.023 172.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 58.7 p -100.84 154.02 19.0 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.847 -178.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -81.73 48.77 1.24 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.098 0.475 . . . . 0.0 110.751 -178.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 93.1 mttt -119.57 166.49 13.09 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . 0.525 ' HB2' ' HZ3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -94.46 144.73 25.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.7 178.705 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 48.0 m -69.86 163.35 26.09 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.287 -176.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -107.18 36.15 2.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.336 0.589 . . . . 0.0 110.546 -175.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.81 82.02 1.53 Allowed Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.224 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.8 -40.85 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.595 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 41.1 t -142.49 -176.04 4.69 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -142.3 28.72 1.66 Allowed 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.513 0.673 . . . . 0.0 109.377 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.37 -36.06 79.18 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.151 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 7.9 p -63.76 -41.68 97.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.161 0.505 . . . . 0.0 110.645 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . 0.451 ' O ' HG22 ' 1' ' 20' ' ' VAL . 54.0 t -66.72 -47.07 84.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.574 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -60.04 -30.9 69.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.326 178.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 79.1 ttt180 -67.43 -21.16 65.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.04 0.447 . . . . 0.0 110.5 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -95.0 -33.61 12.66 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.088 0.471 . . . . 0.0 110.223 177.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . 0.451 HG22 ' O ' ' 1' ' 16' ' ' VAL . 63.3 t -72.39 -67.97 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.284 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . 0.426 HG13 ' H ' ' 1' ' 23' ' ' VAL . 43.8 pt -97.86 -12.96 8.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.754 0.311 . . . . 0.0 111.501 -176.088 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.56 4.95 63.59 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.963 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . 0.426 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -121.41 146.41 26.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.45 38.9 1.23 Allowed 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.115 0.483 . . . . 0.0 110.956 -175.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -109.98 113.34 25.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.621 176.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -168.51 162.8 36.59 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.21 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 55.6 mtmt -141.06 175.29 9.74 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 18.0 t -105.9 111.42 24.06 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.05 177.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 58.9 mt -118.29 112.13 36.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.787 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 59.39 29.23 18.77 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.425 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.74 85.6 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.317 -178.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 33.4 mmt180 -114.27 162.3 16.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.036 0.446 . . . . 0.0 110.801 179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 63.6 m -98.71 109.76 22.46 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.058 -173.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -97.28 122.26 48.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.031 0.443 . . . . 0.0 110.087 176.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 68.3 m -101.07 140.0 35.98 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.614 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -116.04 98.51 51.33 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.788 -179.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 122.65 2.233 . . . . 0.0 112.203 177.806 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 46.7 mt . . . . . 0 N--CA 1.453 -0.282 0 CA-C-O 120.815 0.341 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 47.4 mt-10 -74.38 100.66 3.85 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.167 0.508 . . . . 0.0 110.273 174.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 73.4 p -90.05 168.07 12.27 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.091 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -87.89 13.94 9.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.377 0.608 . . . . 0.0 110.009 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -73.58 148.45 42.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.775 176.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . 0.48 ' N ' ' HD2' ' 1' ' 7' ' ' LYS . 12.7 mptt -95.19 145.85 24.74 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.585 -178.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . 0.669 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 12.8 m -59.42 153.56 18.95 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.735 -175.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -135.05 108.78 8.01 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.903 -177.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 76.88 16.95 80.33 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.906 -178.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.8 1.01 63.76 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.557 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 96.6 p -150.96 -179.42 7.28 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.757 0.313 . . . . 0.0 110.747 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . 0.669 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 92.5 m -133.74 25.15 4.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.009 0.433 . . . . 0.0 110.908 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.27 75.86 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.628 179.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -73.4 -29.54 62.67 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.414 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 88.3 t -63.69 -56.28 17.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.2 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.478 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 95.8 m -66.62 -22.35 66.12 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.367 -178.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -63.54 -24.33 67.77 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.07 0.462 . . . . 0.0 110.228 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -96.17 -35.18 11.4 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.375 176.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 68.4 t -70.44 -64.32 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.48 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . 0.418 HG13 ' H ' ' 1' ' 23' ' ' VAL . 40.1 pt -97.9 -30.2 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.756 0.312 . . . . 0.0 111.158 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.46 -32.45 4.3 Favored Glycine 0 CA--C 1.508 -0.372 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.535 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . 0.418 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.0 t -89.69 147.65 5.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.815 0.341 . . . . 0.0 110.154 -178.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.2 48.42 1.5 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.227 0.536 . . . . 0.0 111.225 -175.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -124.62 112.47 16.84 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.054 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.09 125.14 1.3 Allowed Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.041 -177.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 56.9 mtpt -107.66 165.71 11.22 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.945 0.402 . . . . 0.0 110.719 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.4 t -100.75 100.17 10.81 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.721 -177.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 67.5 mt -109.18 107.39 22.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.556 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 57.01 32.06 21.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.401 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 87.6 -1.15 85.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.632 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 11.2 mpt_? -105.56 157.47 17.37 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.952 0.406 . . . . 0.0 110.62 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 90.3 m -100.47 110.34 22.52 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.591 -175.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . 0.52 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -92.96 107.85 19.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.698 0.761 . . . . 0.0 110.017 175.317 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 66.4 m -85.56 139.22 31.63 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.564 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -117.84 101.76 51.78 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.343 178.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo . . . . . 0 C--O 1.248 1.003 0 C-N-CA 122.641 2.227 . . . . 0.0 112.437 179.835 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.0 mt . . . . . 0 N--CA 1.456 -0.15 0 CA-C-O 120.566 0.222 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 33.5 mt-10 -74.04 90.39 1.99 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.099 0.476 . . . . 0.0 110.293 173.169 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 69.2 p -75.75 156.15 34.89 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.265 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -83.3 37.35 0.56 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.761 0.791 . . . . 0.0 110.314 -178.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -111.42 152.98 26.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.509 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . 0.405 ' HA ' ' O ' ' 1' ' 31' ' ' GLY . 0.8 OUTLIER -93.64 138.46 31.85 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.795 0.331 . . . . 0.0 110.675 -179.206 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . 0.592 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 1.5 p -57.45 148.39 23.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.506 -177.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -91.02 66.6 5.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.408 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 78.8 45.92 8.92 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.463 178.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 118.43 -69.04 0.33 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.525 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 15.2 m -109.15 176.08 5.22 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.938 0.399 . . . . 0.0 110.689 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . 0.592 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 83.1 m -124.02 30.51 6.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.621 -178.322 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 -50.03 75.43 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.647 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.9 m -67.52 -39.15 85.08 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.053 179.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . 0.44 ' O ' HG21 ' 1' ' 20' ' ' VAL . 59.1 t -61.8 -55.91 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.783 -178.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 74.6 m -67.02 -26.69 66.9 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.07 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -64.87 -30.44 71.44 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.108 0.48 . . . . 0.0 110.237 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -83.58 -32.83 25.59 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.504 178.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . 0.44 HG21 ' O ' ' 1' ' 16' ' ' VAL . 60.6 t -81.78 -64.59 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.807 -176.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . 0.437 HG13 ' H ' ' 1' ' 23' ' ' VAL . 45.4 pt -100.05 -9.71 8.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.63 -175.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.29 2.68 70.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.904 177.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . 0.437 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -116.73 143.48 26.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.15 39.64 1.08 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.474 0.655 . . . . 0.0 111.222 -175.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -115.33 109.69 18.29 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.625 175.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -165.32 129.77 2.03 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.047 -176.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -118.98 169.27 10.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . 0.473 ' HA ' ' O ' ' 1' ' 32' ' ' ARG . 11.7 t -106.25 116.72 32.42 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-O 120.969 0.414 . . . . 0.0 110.611 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 75.8 mt -116.42 105.29 18.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.015 177.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 86.3 m-20 55.63 39.24 30.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.318 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . 0.405 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 85.67 4.04 85.63 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.898 178.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . 0.473 ' O ' ' HA ' ' 1' ' 28' ' ' CYS . 10.6 mpt_? -107.75 158.82 16.97 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.858 0.361 . . . . 0.0 110.731 178.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . 0.473 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 21.2 m -103.44 106.39 16.89 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.366 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . 0.447 ' O ' HG13 ' 1' ' 34' ' ' VAL . 6.0 p -88.65 104.65 14.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.706 0.765 . . . . 0.0 110.011 175.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 72.2 m -83.11 136.61 34.4 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -114.83 100.23 53.14 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.471 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 C--O 1.249 1.041 0 C-N-CA 123.03 2.487 . . . . 0.0 111.337 174.854 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.8 mt . . . . . 0 N--CA 1.455 -0.182 0 CA-C-O 120.561 0.219 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.15 115.06 13.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.96 0.41 . . . . 0.0 110.122 173.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 50.9 p -105.16 158.67 16.42 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.348 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -87.17 53.18 2.73 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.617 0.722 . . . . 0.0 109.738 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -128.07 157.96 39.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.159 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 32.4 mttp -86.69 147.77 25.73 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.872 -177.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -89.59 171.12 9.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.892 -179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 16.1 mp0 -95.44 26.99 3.56 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.913 179.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 88.27 91.11 1.09 Allowed Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.829 -177.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.29 -47.44 3.09 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.679 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 48.9 m -127.31 172.36 10.68 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.149 0.499 . . . . 0.0 111.464 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . 0.855 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 49.2 t -138.47 37.56 2.25 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.207 -179.086 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.39 -46.85 85.58 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.956 -175.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 13.1 p -71.84 -39.86 69.44 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -174.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . 0.855 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 76.4 t -63.83 -54.95 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.59 0.233 . . . . 0.0 110.519 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 94.0 m -58.34 -34.0 70.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.79 178.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 51.1 ttp180 -64.84 -29.57 70.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.931 0.396 . . . . 0.0 110.706 178.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -86.49 -40.0 15.71 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.222 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . 0.467 HG22 ' O ' ' 1' ' 16' ' ' VAL . 59.3 t -68.43 -68.13 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.45 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 32.2 pt -101.48 -32.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.813 -174.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 134.46 -41.87 1.41 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.019 -1.086 . . . . 0.0 113.56 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.9 m -78.35 148.03 6.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.989 0.394 . . . . 0.0 110.952 -176.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -96.32 33.3 1.8 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.399 0.619 . . . . 0.0 110.204 179.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -107.0 110.63 22.83 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.528 175.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -163.51 141.28 7.02 Favored Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.669 -176.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -122.36 175.87 6.19 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.823 0.344 . . . . 0.0 110.279 -177.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 19.2 t -115.91 109.5 17.69 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.834 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 74.3 mt -107.31 108.02 24.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.072 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 56.77 40.35 29.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.546 177.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.24 1.19 90.33 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.617 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . 0.467 ' HA ' ' HE ' ' 1' ' 32' ' ' ARG . 1.1 mmp_? -105.67 165.27 11.29 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.971 0.415 . . . . 0.0 110.424 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 15.1 t -101.88 129.53 48.15 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.545 -176.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 p -120.92 115.78 47.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.255 0.55 . . . . 0.0 110.286 175.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 80.3 m -88.48 141.1 28.81 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.107 -177.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -120.05 88.43 40.89 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.213 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo . . . . . 0 C--O 1.248 1.016 0 C-N-CA 122.788 2.325 . . . . 0.0 112.51 -178.562 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 55.2 mt . . . . . 0 N--CA 1.452 -0.371 0 CA-C-O 121.266 0.555 . . . . 0.0 110.782 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 43.1 mt-10 -70.77 132.94 46.09 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.167 173.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 66.8 p -128.04 168.02 15.9 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.038 0.447 . . . . 0.0 110.373 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -85.98 -3.96 59.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.327 0.584 . . . . 0.0 110.391 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 27.7 mtpp -65.51 150.54 48.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.744 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -88.08 144.41 26.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.892 -174.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 5.0 m -68.5 168.57 12.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.114 -174.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 27.4 mm-40 -124.0 64.32 1.06 Allowed 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.784 -177.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.31 39.51 6.35 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.756 177.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.5 -6.05 74.4 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.248 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 87.9 p -133.76 -175.06 3.7 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . 0.864 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 25.6 t -143.73 29.26 1.39 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.362 0.601 . . . . 0.0 109.779 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.62 -47.24 86.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.383 -176.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.02 -38.17 79.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.595 -177.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . 0.864 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 54.2 t -69.9 -50.85 45.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.885 0.374 . . . . 0.0 110.593 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 83.9 m -60.77 -31.2 70.56 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.975 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . 0.423 ' O ' ' HA2' ' 1' ' 22' ' ' GLY . 49.5 ttp180 -64.46 -25.16 67.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.109 0.481 . . . . 0.0 110.161 178.548 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -85.49 -44.58 12.58 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.403 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.9 t -69.38 -66.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.925 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . 0.451 HG13 ' H ' ' 1' ' 23' ' ' VAL . 38.0 pt -94.28 -22.86 5.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.701 0.286 . . . . 0.0 111.5 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' 1' ' 18' ' ' ARG . . . 99.77 10.79 45.68 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.439 -0.886 . . . . 0.0 112.616 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . 0.451 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.9 t -126.13 146.71 31.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.97 38.85 1.07 Allowed 'General case' 0 C--N 1.314 -0.976 0 CA-C-O 121.516 0.674 . . . . 0.0 110.597 -176.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -111.24 108.54 18.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-N 115.267 -0.878 . . . . 0.0 109.536 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.3 140.02 6.1 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.03 -175.548 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . 0.42 ' HE2' ' CE1' ' 1' ' 36' ' ' TYR . 52.0 mtmt -123.61 177.5 5.65 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.837 0.351 . . . . 0.0 110.436 -177.152 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 22.2 t -113.96 115.69 28.05 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.597 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 79.4 mt -112.12 101.85 13.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.249 177.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 53.98 43.07 31.34 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.62 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.4 9.62 85.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.851 178.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 50.1 mmt-85 -118.76 150.71 39.34 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.0 110.179 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 10.3 t -85.31 144.31 28.15 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.067 -176.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . 0.449 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 6.8 p -135.19 116.77 20.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.287 0.565 . . . . 0.0 110.168 173.711 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 99.8 m -95.14 138.3 33.03 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.624 -175.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . 0.42 ' CE1' ' HE2' ' 1' ' 27' ' ' LYS . 19.4 m-85 -116.2 98.34 51.17 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.247 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo . . . . . 0 C--O 1.25 1.122 0 C-N-CA 122.933 2.422 . . . . 0.0 111.938 177.654 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 51.4 mt . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.766 0.317 . . . . 0.0 111.278 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -71.08 93.46 1.03 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.886 0.375 . . . . 0.0 110.644 175.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 46.7 p -81.68 149.77 28.35 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.232 177.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -82.29 53.95 2.42 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.368 0.604 . . . . 0.0 110.438 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -109.69 146.07 35.47 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.482 178.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 45.8 mtpt -79.49 133.45 36.51 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 172.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . 0.633 ' HA ' ' SG ' ' 1' ' 33' ' ' CYS . 3.8 m -56.06 139.68 46.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.156 0.503 . . . . 0.0 110.69 -177.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 28.9 tt0 -89.23 56.58 3.71 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.693 -174.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 103.38 -71.53 0.28 Allowed Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.735 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -132.78 -30.2 0.5 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.25 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 5.4 m -132.75 -178.75 5.08 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . 0.486 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 1.1 m -134.09 35.59 3.28 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.271 174.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.14 -48.74 80.21 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.014 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.6 m -68.9 -32.84 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.198 0.523 . . . . 0.0 110.29 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 55.4 t -62.96 -53.76 42.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.441 177.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 82.5 m -66.38 -24.45 66.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.43 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -63.23 -28.46 70.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.09 0.472 . . . . 0.0 110.064 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -89.41 -36.59 15.38 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.28 178.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.1 t -73.63 -61.37 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.819 -177.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 44.4 pt -106.98 -5.96 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -175.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.72 11.12 71.54 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.542 -0.837 . . . . 0.0 113.176 176.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -122.15 143.89 33.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.74 46.07 1.22 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.516 0.674 . . . . 0.0 110.886 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . 0.478 ' HB2' ' O ' ' 1' ' 36' ' ' TYR . . . -129.23 114.14 15.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.739 175.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -157.65 120.21 0.96 Allowed Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.523 -177.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -108.22 157.2 18.54 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 -174.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 44.5 t -101.14 122.95 44.51 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.827 -177.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 54.6 mt -126.89 103.22 10.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.298 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 52.81 44.47 30.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.593 -0.731 . . . . 0.0 112.153 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.55 -19.93 51.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.24 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -100.37 163.79 12.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -178.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . 0.633 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 76.4 m -118.94 124.93 48.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.195 0.522 . . . . 0.0 111.765 -175.27 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 2.7 p -102.96 121.3 53.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.285 177.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 73.3 m -90.02 138.97 31.07 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.594 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . 0.478 ' O ' ' HB2' ' 1' ' 25' ' ' ALA . 70.1 m-85 -118.16 109.77 40.4 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.115 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo . . . . . 0 C--O 1.249 1.043 0 C-N-CA 122.837 2.358 . . . . 0.0 112.563 178.815 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 67.5 mt . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.976 0.417 . . . . 0.0 111.376 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -70.78 120.09 15.88 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.805 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 76.2 p -113.47 161.98 16.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.358 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -87.23 13.85 8.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 110.88 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -85.29 156.1 21.07 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.706 -176.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt -80.41 146.95 31.21 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.773 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 m -71.76 160.93 31.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.414 -175.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 17.6 tp60 -106.41 68.43 0.76 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.73 -177.091 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.64 45.28 54.03 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.736 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.54 -30.36 9.96 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.69 178.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 94.4 p -114.67 -161.98 0.8 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . 0.861 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 30.2 t -144.93 28.49 1.25 Allowed 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.692 0.758 . . . . 0.0 109.175 172.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.9 -61.65 2.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.112 -177.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.21 -20.35 63.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . 0.861 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 67.2 t -77.58 -58.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.741 0.305 . . . . 0.0 110.212 179.182 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 73.7 m -59.73 -30.33 68.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.354 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -56.51 -35.11 67.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.853 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -91.41 -35.93 14.09 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.75 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.6 t -71.48 -61.64 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.609 -177.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . 0.487 HG13 ' H ' ' 1' ' 23' ' ' VAL . 39.5 pt -102.33 -30.02 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.786 -0.366 . . . . 0.0 111.709 -176.025 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.04 -25.57 6.36 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.056 178.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . 0.487 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.2 t -95.96 148.29 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.52 28.31 3.83 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.073 0.464 . . . . 0.0 111.367 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -105.95 120.08 40.83 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.728 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -167.39 139.6 5.81 Favored Glycine 0 N--CA 1.441 -1.026 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.801 -178.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 60.8 mtpt -118.31 173.02 7.05 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.659 0.266 . . . . 0.0 110.296 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 38.9 t -115.9 127.1 54.74 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.037 -177.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 57.0 mt -124.8 104.44 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.192 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 58.77 34.33 23.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.14 178.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.08 12.83 72.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.36 179.162 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 12.9 mmt85 -120.66 153.76 36.44 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.8 0.333 . . . . 0.0 110.175 176.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 5.8 t -94.41 142.01 27.91 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.184 0.516 . . . . 0.0 111.576 -172.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.16 115.64 27.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.895 172.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 75.6 m -85.09 142.0 29.85 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.065 -177.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 46.3 m-85 -122.16 94.14 48.16 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.01 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo . . . . . 0 C--O 1.25 1.105 0 C-N-CA 123.185 2.59 . . . . 0.0 111.589 175.805 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 33.8 mt . . . . . 0 N--CA 1.453 -0.309 0 CA-C-O 120.652 0.263 . . . . 0.0 110.728 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . 0.418 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 9.2 mp0 -76.81 104.71 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 174.538 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 57.8 p -94.51 165.74 12.39 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.473 -0.331 . . . . 0.0 110.537 -178.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -91.63 28.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.112 0.482 . . . . 0.0 111.204 -178.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 31.5 mtmm -93.68 149.62 21.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.275 176.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -84.96 143.11 29.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.718 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . 0.697 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 3.6 m -57.56 152.26 15.27 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.751 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 8.6 tp-100 -118.05 69.59 0.79 Allowed 'General case' 0 N--CA 1.451 -0.411 0 CA-C-O 121.224 0.535 . . . . 0.0 110.118 -177.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.83 59.97 1.64 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 177.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.51 -34.98 2.86 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.073 176.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 50.1 m -133.22 -179.77 5.71 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.877 0.37 . . . . 0.0 110.506 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . 0.697 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.0 m -132.14 30.2 4.26 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.937 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -60.66 -48.79 80.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.272 -177.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . 0.435 ' HA ' ' HE ' ' 1' ' 18' ' ' ARG . 25.3 m -75.04 -25.92 59.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.957 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . 0.53 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.0 t -62.07 -56.58 16.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.104 0.478 . . . . 0.0 109.798 175.097 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 66.7 m -66.88 -24.64 66.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.144 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . 0.435 ' HE ' ' HA ' ' 1' ' 15' ' ' SER . 10.1 ttm-85 -62.92 -30.73 71.77 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-O 121.225 0.536 . . . . 0.0 109.77 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -87.95 -38.79 15.26 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.778 178.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . 0.53 HG23 ' O ' ' 1' ' 16' ' ' VAL . 43.8 t -68.45 -66.02 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.257 -177.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 31.2 pt -109.65 -10.46 11.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.83 0.348 . . . . 0.0 111.735 -175.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 109.48 -32.87 6.46 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.345 -0.931 . . . . 0.0 113.381 174.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . 0.475 HG23 ' O ' ' 1' ' 36' ' ' TYR . 14.6 m -81.76 144.79 9.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.997 0.427 . . . . 0.0 110.774 -177.081 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.54 44.23 1.17 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.483 0.659 . . . . 0.0 110.329 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -117.68 106.19 12.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.817 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . 0.65 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -163.36 126.2 1.5 Allowed Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.037 -176.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -112.16 164.98 12.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.81 0.338 . . . . 0.0 111.103 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.7 t -102.89 93.91 5.3 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.094 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 60.0 mt -104.17 105.74 19.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.309 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.08 37.48 21.01 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 123.293 0.371 . . . . 0.0 111.595 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.06 26.49 70.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.883 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -126.05 156.32 40.15 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . 0.402 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 62.9 m -105.87 110.03 22.18 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.001 0.429 . . . . 0.0 111.132 -177.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . 0.65 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -98.88 119.45 46.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.275 176.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.0 m -95.85 138.51 33.39 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.619 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . 0.475 ' O ' HG23 ' 1' ' 23' ' ' VAL . 37.7 m-85 -114.0 100.82 53.21 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.857 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo . . . . . 0 C--O 1.251 1.175 0 C-N-CA 122.832 2.355 . . . . 0.0 112.414 178.496 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 44.7 mm . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.683 0.278 . . . . 0.0 111.196 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -75.5 99.24 4.16 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 172.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 4' ' ' THR . . . . . 0.406 ' C ' ' H ' ' 1' ' 6' ' ' LYS . 82.4 p -90.08 154.91 19.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.638 -178.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 5' ' ' ASN . . . . . 0.45 ' HA ' ' HD2' ' 1' ' 32' ' ' ARG . 86.2 m-20 -81.14 31.22 0.32 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.986 0.422 . . . . 0.0 111.414 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 6' ' ' LYS . . . . . 0.406 ' H ' ' C ' ' 1' ' 4' ' ' THR . 55.7 mttp -93.8 139.41 30.89 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.831 177.431 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 7' ' ' LYS . . . . . 0.474 ' H ' ' HD3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -74.1 146.64 43.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.095 177.508 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' 1' 1 ' 8' ' ' CYS . . . . . 0.734 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.2 m -61.98 153.07 30.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.137 -176.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -98.25 76.72 2.35 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.297 0.57 . . . . 0.0 109.483 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -70.65 3.1 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.231 -178.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.63 -23.89 0.5 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.981 -179.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 47.5 m -141.2 -177.94 5.35 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 122.634 -0.333 . . . . 0.0 110.158 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 13' ' ' CYS . . . . . 0.734 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 72.7 m -131.43 25.04 4.81 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.093 0.473 . . . . 0.0 110.803 -178.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.281 -178.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 20.4 m -70.78 -31.24 67.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.707 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 16' ' ' VAL . . . . . 0.464 ' O ' HG23 ' 1' ' 20' ' ' VAL . 77.5 t -62.4 -53.4 47.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.05 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 79.1 m -65.82 -29.98 70.54 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.918 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.4 ttt180 -65.5 -31.37 72.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.147 0.499 . . . . 0.0 110.268 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -81.99 -40.16 22.57 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.719 177.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 20' ' ' VAL . . . . . 0.464 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.4 t -70.77 -70.28 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.535 -178.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 28.8 pt -100.21 -29.23 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -174.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.1 -37.03 2.37 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.072 -1.061 . . . . 0.0 113.378 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.4 m -74.78 145.91 10.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 117.002 0.401 . . . . 0.0 110.673 -178.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -95.64 40.65 1.11 Allowed 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.396 0.617 . . . . 0.0 110.484 -178.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -119.18 106.77 12.69 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.518 175.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 26' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -157.43 120.52 0.99 Allowed Glycine 0 N--CA 1.444 -0.826 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.305 -177.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 57.0 mtpt -111.17 159.07 18.21 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 120.983 0.42 . . . . 0.0 111.14 -174.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 53.8 t -97.37 114.78 26.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.601 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 69.9 mt -123.09 103.13 12.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.429 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 55.12 36.41 26.92 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.801 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 83.59 22.3 56.38 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.347 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 32' ' ' ARG . . . . . 0.45 ' HD2' ' HA ' ' 1' ' 5' ' ' ASN . 36.6 mmt180 -124.28 156.21 37.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.699 0.285 . . . . 0.0 110.408 177.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 88.8 m -108.12 107.45 18.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.227 -177.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 34' ' ' VAL . . . . . 0.456 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 3.6 p -94.38 111.82 25.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.43 0.633 . . . . 0.0 110.233 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.11 139.58 30.43 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -118.43 90.02 37.83 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.001 -178.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo . . . . . 0 C--O 1.248 1.017 0 C-N-CA 122.641 2.227 . . . . 0.0 111.833 176.267 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.815 0 CA-C-O 120.635 0.255 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 39.3 mm -95.62 91.6 2.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.176 0.513 . . . . 0.0 110.525 -177.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -81.75 92.96 6.72 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.756 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 75.5 p -86.4 145.62 26.79 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.11 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -83.64 52.47 2.26 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.737 0.779 . . . . 0.0 110.252 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 67.4 mttm -105.88 157.62 17.35 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.32 177.458 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . 0.527 ' HD2' ' O ' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -82.15 144.5 30.7 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.716 0.293 . . . . 0.0 110.262 177.984 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . 0.632 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.7 m -67.67 150.09 49.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.71 -177.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -96.47 72.26 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 94.97 -77.96 0.88 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.567 -177.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.3 -15.27 0.9 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 16.2 m -144.36 -177.61 5.56 Favored 'General case' 0 C--N 1.324 -0.519 0 O-C-N 122.591 -0.358 . . . . 0.0 110.131 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . 0.632 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.9 m -134.78 27.26 3.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.636 -177.439 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.31 -47.22 83.15 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.425 -178.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 18.6 t -70.61 -30.71 67.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.131 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . 0.491 ' O ' HG22 ' 1' ' 20' ' ' VAL . 95.7 t -62.71 -54.07 38.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.223 175.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.71 -28.04 68.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.128 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -64.65 -27.04 68.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.138 176.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 1.5 tmtp? -87.9 -46.28 9.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.881 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . 0.491 HG22 ' O ' ' 1' ' 16' ' ' VAL . 57.9 t -61.86 -60.36 2.83 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.898 -176.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 19.1 pt -109.06 -34.82 2.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.616 -0.265 . . . . 0.0 111.683 -176.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 135.72 -39.87 1.61 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.052 -1.071 . . . . 0.0 113.145 177.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 29.5 m -79.13 147.32 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.962 0.41 . . . . 0.0 110.865 -177.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.71 42.32 1.1 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.448 0.642 . . . . 0.0 110.318 -179.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -116.07 108.22 15.93 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.896 178.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -171.86 131.19 2.1 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.947 -177.448 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -125.93 166.17 17.41 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.846 0.355 . . . . 0.0 111.147 -173.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.44 91.93 6.05 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.964 -175.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.05 118.88 53.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.94 177.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 57.55 27.77 14.6 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.766 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.12 11.77 84.02 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.337 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . 0.556 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 10.5 mpt_? -116.19 165.8 12.75 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.061 0.458 . . . . 0.0 110.612 178.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 92.0 m -104.22 106.38 16.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.172 -176.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . 0.461 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 2.7 p -97.35 113.15 31.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.38 0.61 . . . . 0.0 110.159 174.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.9 m -85.85 145.6 27.12 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.04 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -119.77 79.66 23.84 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.086 -177.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo . . . . . 0 C--O 1.249 1.069 0 C-N-CA 122.715 2.276 . . . . 0.0 112.521 177.918 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 52.5 mt -107.13 95.35 3.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 120.784 0.326 . . . . 0.0 111.3 -175.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -77.82 114.97 17.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.023 172.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 58.7 p -100.84 154.02 19.0 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.847 -178.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -81.73 48.77 1.24 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.098 0.475 . . . . 0.0 110.751 -178.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 93.1 mttt -119.57 166.49 13.09 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . 0.525 ' HB2' ' HZ3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -94.46 144.73 25.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.7 178.705 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 48.0 m -69.86 163.35 26.09 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.287 -176.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -107.18 36.15 2.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.336 0.589 . . . . 0.0 110.546 -175.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.81 82.02 1.53 Allowed Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.224 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.8 -40.85 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.595 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 41.1 t -142.49 -176.04 4.69 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -142.3 28.72 1.66 Allowed 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.513 0.673 . . . . 0.0 109.377 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.37 -36.06 79.18 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.151 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 7.9 p -63.76 -41.68 97.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.161 0.505 . . . . 0.0 110.645 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . 0.451 ' O ' HG22 ' 1' ' 20' ' ' VAL . 54.0 t -66.72 -47.07 84.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.574 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -60.04 -30.9 69.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.326 178.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 79.1 ttt180 -67.43 -21.16 65.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.04 0.447 . . . . 0.0 110.5 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -95.0 -33.61 12.66 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.088 0.471 . . . . 0.0 110.223 177.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . 0.451 HG22 ' O ' ' 1' ' 16' ' ' VAL . 63.3 t -72.39 -67.97 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.284 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . 0.426 HG13 ' H ' ' 1' ' 23' ' ' VAL . 43.8 pt -97.86 -12.96 8.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.754 0.311 . . . . 0.0 111.501 -176.088 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.56 4.95 63.59 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.963 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . 0.426 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -121.41 146.41 26.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.45 38.9 1.23 Allowed 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.115 0.483 . . . . 0.0 110.956 -175.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -109.98 113.34 25.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.621 176.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -168.51 162.8 36.59 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.21 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 55.6 mtmt -141.06 175.29 9.74 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 18.0 t -105.9 111.42 24.06 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.05 177.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 58.9 mt -118.29 112.13 36.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.787 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 59.39 29.23 18.77 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.425 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.74 85.6 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.317 -178.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 33.4 mmt180 -114.27 162.3 16.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.036 0.446 . . . . 0.0 110.801 179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 63.6 m -98.71 109.76 22.46 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.058 -173.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -97.28 122.26 48.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.031 0.443 . . . . 0.0 110.087 176.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 68.3 m -101.07 140.0 35.98 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.614 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -116.04 98.51 51.33 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.788 -179.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 122.65 2.233 . . . . 0.0 112.203 177.806 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 46.7 mt -124.7 91.84 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.815 0.341 . . . . 0.0 111.079 -179.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 47.4 mt-10 -74.38 100.66 3.85 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.167 0.508 . . . . 0.0 110.273 174.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 73.4 p -90.05 168.07 12.27 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.091 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -87.89 13.94 9.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.377 0.608 . . . . 0.0 110.009 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -73.58 148.45 42.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.775 176.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . 0.48 ' N ' ' HD2' ' 1' ' 7' ' ' LYS . 12.7 mptt -95.19 145.85 24.74 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.585 -178.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . 0.669 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 12.8 m -59.42 153.56 18.95 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.735 -175.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -135.05 108.78 8.01 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.903 -177.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 76.88 16.95 80.33 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.906 -178.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.8 1.01 63.76 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.557 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 96.6 p -150.96 -179.42 7.28 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.757 0.313 . . . . 0.0 110.747 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . 0.669 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 92.5 m -133.74 25.15 4.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.009 0.433 . . . . 0.0 110.908 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.27 75.86 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.628 179.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -73.4 -29.54 62.67 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.414 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 88.3 t -63.69 -56.28 17.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.2 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.478 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 95.8 m -66.62 -22.35 66.12 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.367 -178.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -63.54 -24.33 67.77 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.07 0.462 . . . . 0.0 110.228 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -96.17 -35.18 11.4 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.375 176.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 68.4 t -70.44 -64.32 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.48 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . 0.418 HG13 ' H ' ' 1' ' 23' ' ' VAL . 40.1 pt -97.9 -30.2 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.756 0.312 . . . . 0.0 111.158 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.46 -32.45 4.3 Favored Glycine 0 CA--C 1.508 -0.372 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.535 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . 0.418 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.0 t -89.69 147.65 5.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.815 0.341 . . . . 0.0 110.154 -178.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.2 48.42 1.5 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.227 0.536 . . . . 0.0 111.225 -175.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -124.62 112.47 16.84 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.054 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.09 125.14 1.3 Allowed Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.041 -177.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 56.9 mtpt -107.66 165.71 11.22 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.945 0.402 . . . . 0.0 110.719 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.4 t -100.75 100.17 10.81 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.721 -177.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 67.5 mt -109.18 107.39 22.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.556 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 57.01 32.06 21.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.401 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 87.6 -1.15 85.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.632 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 11.2 mpt_? -105.56 157.47 17.37 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.952 0.406 . . . . 0.0 110.62 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 90.3 m -100.47 110.34 22.52 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.591 -175.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . 0.52 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -92.96 107.85 19.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.698 0.761 . . . . 0.0 110.017 175.317 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 66.4 m -85.56 139.22 31.63 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.564 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -117.84 101.76 51.78 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.343 178.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo . . . . . 0 C--O 1.248 1.003 0 C-N-CA 122.641 2.227 . . . . 0.0 112.437 179.835 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.863 0 N-CA-C 110.324 -0.25 . . . . 0.0 110.324 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.0 mt -124.23 98.87 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.215 -178.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 33.5 mt-10 -74.04 90.39 1.99 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.099 0.476 . . . . 0.0 110.293 173.169 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 69.2 p -75.75 156.15 34.89 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.265 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -83.3 37.35 0.56 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.761 0.791 . . . . 0.0 110.314 -178.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -111.42 152.98 26.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.509 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . 0.405 ' HA ' ' O ' ' 1' ' 31' ' ' GLY . 0.8 OUTLIER -93.64 138.46 31.85 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.795 0.331 . . . . 0.0 110.675 -179.206 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . 0.592 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 1.5 p -57.45 148.39 23.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.506 -177.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -91.02 66.6 5.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.408 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 78.8 45.92 8.92 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.463 178.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 118.43 -69.04 0.33 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.525 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 15.2 m -109.15 176.08 5.22 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.938 0.399 . . . . 0.0 110.689 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . 0.592 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 83.1 m -124.02 30.51 6.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.621 -178.322 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 -50.03 75.43 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.647 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.9 m -67.52 -39.15 85.08 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.053 179.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . 0.44 ' O ' HG21 ' 1' ' 20' ' ' VAL . 59.1 t -61.8 -55.91 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.783 -178.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 74.6 m -67.02 -26.69 66.9 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.07 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -64.87 -30.44 71.44 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.108 0.48 . . . . 0.0 110.237 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -83.58 -32.83 25.59 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.504 178.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . 0.44 HG21 ' O ' ' 1' ' 16' ' ' VAL . 60.6 t -81.78 -64.59 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.807 -176.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . 0.437 HG13 ' H ' ' 1' ' 23' ' ' VAL . 45.4 pt -100.05 -9.71 8.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.63 -175.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.29 2.68 70.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.904 177.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . 0.437 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -116.73 143.48 26.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.15 39.64 1.08 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.474 0.655 . . . . 0.0 111.222 -175.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -115.33 109.69 18.29 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.625 175.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -165.32 129.77 2.03 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.047 -176.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -118.98 169.27 10.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . 0.473 ' HA ' ' O ' ' 1' ' 32' ' ' ARG . 11.7 t -106.25 116.72 32.42 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-O 120.969 0.414 . . . . 0.0 110.611 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 75.8 mt -116.42 105.29 18.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.015 177.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 86.3 m-20 55.63 39.24 30.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.318 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . 0.405 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 85.67 4.04 85.63 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.898 178.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . 0.473 ' O ' ' HA ' ' 1' ' 28' ' ' CYS . 10.6 mpt_? -107.75 158.82 16.97 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.858 0.361 . . . . 0.0 110.731 178.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . 0.473 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 21.2 m -103.44 106.39 16.89 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.366 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . 0.447 ' O ' HG13 ' 1' ' 34' ' ' VAL . 6.0 p -88.65 104.65 14.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.706 0.765 . . . . 0.0 110.011 175.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 72.2 m -83.11 136.61 34.4 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -114.83 100.23 53.14 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.471 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 C--O 1.249 1.041 0 C-N-CA 123.03 2.487 . . . . 0.0 111.337 174.854 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 120.725 0.297 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.8 mt -124.04 96.36 3.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.796 -179.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.15 115.06 13.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.96 0.41 . . . . 0.0 110.122 173.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 50.9 p -105.16 158.67 16.42 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.348 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -87.17 53.18 2.73 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.617 0.722 . . . . 0.0 109.738 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -128.07 157.96 39.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.159 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 32.4 mttp -86.69 147.77 25.73 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.872 -177.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -89.59 171.12 9.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.892 -179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 16.1 mp0 -95.44 26.99 3.56 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.913 179.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 88.27 91.11 1.09 Allowed Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.829 -177.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.29 -47.44 3.09 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.679 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 48.9 m -127.31 172.36 10.68 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.149 0.499 . . . . 0.0 111.464 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . 0.855 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 49.2 t -138.47 37.56 2.25 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.207 -179.086 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.39 -46.85 85.58 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.956 -175.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 13.1 p -71.84 -39.86 69.44 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -174.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . 0.855 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 76.4 t -63.83 -54.95 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.59 0.233 . . . . 0.0 110.519 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 94.0 m -58.34 -34.0 70.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.79 178.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 51.1 ttp180 -64.84 -29.57 70.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.931 0.396 . . . . 0.0 110.706 178.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -86.49 -40.0 15.71 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.222 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . 0.467 HG22 ' O ' ' 1' ' 16' ' ' VAL . 59.3 t -68.43 -68.13 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.45 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 32.2 pt -101.48 -32.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.813 -174.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 134.46 -41.87 1.41 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.019 -1.086 . . . . 0.0 113.56 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.9 m -78.35 148.03 6.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.989 0.394 . . . . 0.0 110.952 -176.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -96.32 33.3 1.8 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.399 0.619 . . . . 0.0 110.204 179.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -107.0 110.63 22.83 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.528 175.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -163.51 141.28 7.02 Favored Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.669 -176.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -122.36 175.87 6.19 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.823 0.344 . . . . 0.0 110.279 -177.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 19.2 t -115.91 109.5 17.69 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.834 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 74.3 mt -107.31 108.02 24.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.072 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 56.77 40.35 29.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.546 177.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.24 1.19 90.33 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.617 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . 0.467 ' HA ' ' HE ' ' 1' ' 32' ' ' ARG . 1.1 mmp_? -105.67 165.27 11.29 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.971 0.415 . . . . 0.0 110.424 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 15.1 t -101.88 129.53 48.15 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.545 -176.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 p -120.92 115.78 47.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.255 0.55 . . . . 0.0 110.286 175.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 80.3 m -88.48 141.1 28.81 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.107 -177.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -120.05 88.43 40.89 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.213 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo . . . . . 0 C--O 1.248 1.016 0 C-N-CA 122.788 2.325 . . . . 0.0 112.51 -178.562 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . 0.504 ' HB3' ' CG2' ' 1' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.475 0.805 0 CA-C-O 120.64 0.257 . . . . 0.0 110.491 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 55.2 mt -89.01 90.7 3.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.266 0.555 . . . . 0.0 110.782 -177.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 43.1 mt-10 -70.77 132.94 46.09 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.167 173.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 66.8 p -128.04 168.02 15.9 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.038 0.447 . . . . 0.0 110.373 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -85.98 -3.96 59.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.327 0.584 . . . . 0.0 110.391 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 27.7 mtpp -65.51 150.54 48.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.744 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -88.08 144.41 26.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.892 -174.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 5.0 m -68.5 168.57 12.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.114 -174.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 27.4 mm-40 -124.0 64.32 1.06 Allowed 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.784 -177.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.31 39.51 6.35 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.756 177.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.5 -6.05 74.4 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.248 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 87.9 p -133.76 -175.06 3.7 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . 0.864 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 25.6 t -143.73 29.26 1.39 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.362 0.601 . . . . 0.0 109.779 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.62 -47.24 86.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.383 -176.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.02 -38.17 79.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.595 -177.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . 0.864 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 54.2 t -69.9 -50.85 45.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.885 0.374 . . . . 0.0 110.593 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 83.9 m -60.77 -31.2 70.56 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.975 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . 0.423 ' O ' ' HA2' ' 1' ' 22' ' ' GLY . 49.5 ttp180 -64.46 -25.16 67.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.109 0.481 . . . . 0.0 110.161 178.548 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -85.49 -44.58 12.58 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.403 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.9 t -69.38 -66.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.925 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . 0.451 HG13 ' H ' ' 1' ' 23' ' ' VAL . 38.0 pt -94.28 -22.86 5.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.701 0.286 . . . . 0.0 111.5 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' 1' ' 18' ' ' ARG . . . 99.77 10.79 45.68 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.439 -0.886 . . . . 0.0 112.616 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . 0.451 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.9 t -126.13 146.71 31.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.97 38.85 1.07 Allowed 'General case' 0 C--N 1.314 -0.976 0 CA-C-O 121.516 0.674 . . . . 0.0 110.597 -176.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -111.24 108.54 18.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-N 115.267 -0.878 . . . . 0.0 109.536 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.3 140.02 6.1 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.03 -175.548 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . 0.42 ' HE2' ' CE1' ' 1' ' 36' ' ' TYR . 52.0 mtmt -123.61 177.5 5.65 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.837 0.351 . . . . 0.0 110.436 -177.152 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 22.2 t -113.96 115.69 28.05 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.597 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 79.4 mt -112.12 101.85 13.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.249 177.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 53.98 43.07 31.34 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.62 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.4 9.62 85.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.851 178.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 50.1 mmt-85 -118.76 150.71 39.34 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.0 110.179 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 10.3 t -85.31 144.31 28.15 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.067 -176.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . 0.504 ' CG2' ' HB3' ' 1' ' 1' ' ' PCA . 6.8 p -135.19 116.77 20.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.287 0.565 . . . . 0.0 110.168 173.711 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 99.8 m -95.14 138.3 33.03 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.624 -175.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . 0.42 ' CE1' ' HE2' ' 1' ' 27' ' ' LYS . 19.4 m-85 -116.2 98.34 51.17 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.247 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo . . . . . 0 C--O 1.25 1.122 0 C-N-CA 122.933 2.422 . . . . 0.0 111.938 177.654 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.778 0 N-CA-C 110.386 -0.227 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 51.4 mt -96.46 95.28 4.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.766 0.317 . . . . 0.0 111.278 -175.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -71.08 93.46 1.03 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.886 0.375 . . . . 0.0 110.644 175.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 46.7 p -81.68 149.77 28.35 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.232 177.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -82.29 53.95 2.42 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.368 0.604 . . . . 0.0 110.438 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -109.69 146.07 35.47 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.482 178.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 45.8 mtpt -79.49 133.45 36.51 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 172.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . 0.633 ' HA ' ' SG ' ' 1' ' 33' ' ' CYS . 3.8 m -56.06 139.68 46.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.156 0.503 . . . . 0.0 110.69 -177.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 28.9 tt0 -89.23 56.58 3.71 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.693 -174.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 103.38 -71.53 0.28 Allowed Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.735 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -132.78 -30.2 0.5 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.25 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 5.4 m -132.75 -178.75 5.08 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . 0.486 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 1.1 m -134.09 35.59 3.28 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.271 174.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.14 -48.74 80.21 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.014 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.6 m -68.9 -32.84 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.198 0.523 . . . . 0.0 110.29 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 55.4 t -62.96 -53.76 42.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.441 177.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 82.5 m -66.38 -24.45 66.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.43 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -63.23 -28.46 70.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.09 0.472 . . . . 0.0 110.064 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -89.41 -36.59 15.38 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.28 178.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.1 t -73.63 -61.37 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.819 -177.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 44.4 pt -106.98 -5.96 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -175.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.72 11.12 71.54 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.542 -0.837 . . . . 0.0 113.176 176.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -122.15 143.89 33.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.74 46.07 1.22 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.516 0.674 . . . . 0.0 110.886 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . 0.478 ' HB2' ' O ' ' 1' ' 36' ' ' TYR . . . -129.23 114.14 15.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.739 175.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -157.65 120.21 0.96 Allowed Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.523 -177.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -108.22 157.2 18.54 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 -174.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 44.5 t -101.14 122.95 44.51 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.827 -177.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 54.6 mt -126.89 103.22 10.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.298 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 52.81 44.47 30.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.593 -0.731 . . . . 0.0 112.153 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.55 -19.93 51.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.24 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -100.37 163.79 12.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -178.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . 0.633 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 76.4 m -118.94 124.93 48.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.195 0.522 . . . . 0.0 111.765 -175.27 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 2.7 p -102.96 121.3 53.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.285 177.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 73.3 m -90.02 138.97 31.07 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.594 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . 0.478 ' O ' ' HB2' ' 1' ' 25' ' ' ALA . 70.1 m-85 -118.16 109.77 40.4 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.115 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo . . . . . 0 C--O 1.249 1.043 0 C-N-CA 122.837 2.358 . . . . 0.0 112.563 178.815 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 CA-C-O 120.796 0.331 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 67.5 mt -108.68 94.83 3.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.976 0.417 . . . . 0.0 111.376 -175.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -70.78 120.09 15.88 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.805 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 76.2 p -113.47 161.98 16.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.358 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -87.23 13.85 8.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 110.88 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -85.29 156.1 21.07 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.706 -176.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt -80.41 146.95 31.21 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.773 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 m -71.76 160.93 31.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.414 -175.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 17.6 tp60 -106.41 68.43 0.76 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.73 -177.091 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.64 45.28 54.03 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.736 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.54 -30.36 9.96 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.69 178.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 94.4 p -114.67 -161.98 0.8 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . 0.861 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 30.2 t -144.93 28.49 1.25 Allowed 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.692 0.758 . . . . 0.0 109.175 172.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.9 -61.65 2.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.112 -177.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.21 -20.35 63.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . 0.861 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 67.2 t -77.58 -58.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.741 0.305 . . . . 0.0 110.212 179.182 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 73.7 m -59.73 -30.33 68.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.354 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -56.51 -35.11 67.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.853 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -91.41 -35.93 14.09 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.75 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.6 t -71.48 -61.64 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.609 -177.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . 0.487 HG13 ' H ' ' 1' ' 23' ' ' VAL . 39.5 pt -102.33 -30.02 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.786 -0.366 . . . . 0.0 111.709 -176.025 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.04 -25.57 6.36 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.056 178.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . 0.487 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.2 t -95.96 148.29 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.52 28.31 3.83 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.073 0.464 . . . . 0.0 111.367 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -105.95 120.08 40.83 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.728 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -167.39 139.6 5.81 Favored Glycine 0 N--CA 1.441 -1.026 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.801 -178.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 60.8 mtpt -118.31 173.02 7.05 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.659 0.266 . . . . 0.0 110.296 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 38.9 t -115.9 127.1 54.74 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.037 -177.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 57.0 mt -124.8 104.44 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.192 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 58.77 34.33 23.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.14 178.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.08 12.83 72.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.36 179.162 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 12.9 mmt85 -120.66 153.76 36.44 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.8 0.333 . . . . 0.0 110.175 176.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 5.8 t -94.41 142.01 27.91 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.184 0.516 . . . . 0.0 111.576 -172.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.16 115.64 27.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.895 172.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 75.6 m -85.09 142.0 29.85 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.065 -177.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 46.3 m-85 -122.16 94.14 48.16 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.01 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo . . . . . 0 C--O 1.25 1.105 0 C-N-CA 123.185 2.59 . . . . 0.0 111.589 175.805 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 120.633 0.254 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 33.8 mt -113.4 93.62 2.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.728 -178.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . 0.418 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 9.2 mp0 -76.81 104.71 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 174.538 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 57.8 p -94.51 165.74 12.39 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.473 -0.331 . . . . 0.0 110.537 -178.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -91.63 28.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.112 0.482 . . . . 0.0 111.204 -178.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 31.5 mtmm -93.68 149.62 21.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.275 176.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -84.96 143.11 29.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.718 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . 0.697 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 3.6 m -57.56 152.26 15.27 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.751 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 8.6 tp-100 -118.05 69.59 0.79 Allowed 'General case' 0 N--CA 1.451 -0.411 0 CA-C-O 121.224 0.535 . . . . 0.0 110.118 -177.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.83 59.97 1.64 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 177.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.51 -34.98 2.86 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.073 176.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 50.1 m -133.22 -179.77 5.71 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.877 0.37 . . . . 0.0 110.506 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . 0.697 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.0 m -132.14 30.2 4.26 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.937 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -60.66 -48.79 80.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.272 -177.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . 0.435 ' HA ' ' HE ' ' 1' ' 18' ' ' ARG . 25.3 m -75.04 -25.92 59.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.957 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . 0.53 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.0 t -62.07 -56.58 16.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.104 0.478 . . . . 0.0 109.798 175.097 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 66.7 m -66.88 -24.64 66.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.144 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . 0.435 ' HE ' ' HA ' ' 1' ' 15' ' ' SER . 10.1 ttm-85 -62.92 -30.73 71.77 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-O 121.225 0.536 . . . . 0.0 109.77 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -87.95 -38.79 15.26 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.778 178.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . 0.53 HG23 ' O ' ' 1' ' 16' ' ' VAL . 43.8 t -68.45 -66.02 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.257 -177.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 31.2 pt -109.65 -10.46 11.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.83 0.348 . . . . 0.0 111.735 -175.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 109.48 -32.87 6.46 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.345 -0.931 . . . . 0.0 113.381 174.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . 0.475 HG23 ' O ' ' 1' ' 36' ' ' TYR . 14.6 m -81.76 144.79 9.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.997 0.427 . . . . 0.0 110.774 -177.081 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.54 44.23 1.17 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.483 0.659 . . . . 0.0 110.329 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -117.68 106.19 12.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.817 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . 0.65 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -163.36 126.2 1.5 Allowed Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.037 -176.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -112.16 164.98 12.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.81 0.338 . . . . 0.0 111.103 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.7 t -102.89 93.91 5.3 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.094 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 60.0 mt -104.17 105.74 19.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.309 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.08 37.48 21.01 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 123.293 0.371 . . . . 0.0 111.595 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.06 26.49 70.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.883 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -126.05 156.32 40.15 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . 0.402 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 62.9 m -105.87 110.03 22.18 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.001 0.429 . . . . 0.0 111.132 -177.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . 0.65 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -98.88 119.45 46.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.275 176.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.0 m -95.85 138.51 33.39 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.619 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . 0.475 ' O ' HG23 ' 1' ' 23' ' ' VAL . 37.7 m-85 -114.0 100.82 53.21 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.857 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo . . . . . 0 C--O 1.251 1.175 0 C-N-CA 122.832 2.355 . . . . 0.0 112.414 178.496 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.758 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 44.7 mm -123.56 101.84 10.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.683 0.278 . . . . 0.0 111.196 -177.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -75.5 99.24 4.16 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 172.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 4' ' ' THR . . . . . 0.406 ' C ' ' H ' ' 1' ' 6' ' ' LYS . 82.4 p -90.08 154.91 19.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.638 -178.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 5' ' ' ASN . . . . . 0.45 ' HA ' ' HD2' ' 1' ' 32' ' ' ARG . 86.2 m-20 -81.14 31.22 0.32 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.986 0.422 . . . . 0.0 111.414 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 6' ' ' LYS . . . . . 0.406 ' H ' ' C ' ' 1' ' 4' ' ' THR . 55.7 mttp -93.8 139.41 30.89 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.831 177.431 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 7' ' ' LYS . . . . . 0.474 ' H ' ' HD3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -74.1 146.64 43.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.095 177.508 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' 1' 1 ' 8' ' ' CYS . . . . . 0.734 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.2 m -61.98 153.07 30.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.137 -176.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -98.25 76.72 2.35 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.297 0.57 . . . . 0.0 109.483 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -70.65 3.1 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.231 -178.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.63 -23.89 0.5 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.981 -179.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 47.5 m -141.2 -177.94 5.35 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 122.634 -0.333 . . . . 0.0 110.158 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 13' ' ' CYS . . . . . 0.734 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 72.7 m -131.43 25.04 4.81 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.093 0.473 . . . . 0.0 110.803 -178.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.281 -178.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 20.4 m -70.78 -31.24 67.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.707 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 16' ' ' VAL . . . . . 0.464 ' O ' HG23 ' 1' ' 20' ' ' VAL . 77.5 t -62.4 -53.4 47.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.05 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 79.1 m -65.82 -29.98 70.54 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.918 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.4 ttt180 -65.5 -31.37 72.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.147 0.499 . . . . 0.0 110.268 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -81.99 -40.16 22.57 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.719 177.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 20' ' ' VAL . . . . . 0.464 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.4 t -70.77 -70.28 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.535 -178.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 28.8 pt -100.21 -29.23 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -174.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.1 -37.03 2.37 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.072 -1.061 . . . . 0.0 113.378 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.4 m -74.78 145.91 10.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 117.002 0.401 . . . . 0.0 110.673 -178.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -95.64 40.65 1.11 Allowed 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.396 0.617 . . . . 0.0 110.484 -178.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -119.18 106.77 12.69 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.518 175.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 26' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -157.43 120.52 0.99 Allowed Glycine 0 N--CA 1.444 -0.826 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.305 -177.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 57.0 mtpt -111.17 159.07 18.21 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 120.983 0.42 . . . . 0.0 111.14 -174.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 53.8 t -97.37 114.78 26.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.601 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 69.9 mt -123.09 103.13 12.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.429 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 55.12 36.41 26.92 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.801 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 83.59 22.3 56.38 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.347 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 32' ' ' ARG . . . . . 0.45 ' HD2' ' HA ' ' 1' ' 5' ' ' ASN . 36.6 mmt180 -124.28 156.21 37.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.699 0.285 . . . . 0.0 110.408 177.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 88.8 m -108.12 107.45 18.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.227 -177.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 34' ' ' VAL . . . . . 0.456 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 3.6 p -94.38 111.82 25.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.43 0.633 . . . . 0.0 110.233 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.11 139.58 30.43 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -118.43 90.02 37.83 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.001 -178.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo . . . . . 0 C--O 1.248 1.017 0 C-N-CA 122.641 2.227 . . . . 0.0 111.833 176.267 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 39.3 mm . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 121.176 0.513 . . . . 0.0 110.525 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . 0.421 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 29.7 mt-10 -81.75 92.96 6.72 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.756 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 75.5 p -86.4 145.62 26.79 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.11 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -83.64 52.47 2.26 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.737 0.779 . . . . 0.0 110.252 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . 0.564 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 67.4 mttm -105.88 157.62 17.35 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.32 177.458 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . 0.536 ' O ' ' HD2' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -82.15 144.5 30.7 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.716 0.293 . . . . 0.0 110.262 177.984 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . 0.641 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.7 m -67.67 150.09 49.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.71 -177.55 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -96.47 72.26 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 94.97 -77.96 0.88 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.567 -177.263 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.3 -15.27 0.9 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 16.2 m -144.36 -177.61 5.56 Favored 'General case' 0 C--N 1.324 -0.519 0 O-C-N 122.591 -0.358 . . . . 0.0 110.131 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . 0.641 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.9 m -134.78 27.26 3.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.636 -177.439 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.31 -47.22 83.15 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.425 -178.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 18.6 t -70.61 -30.71 67.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.131 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . 0.496 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.7 t -62.71 -54.07 38.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.223 175.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.71 -28.04 68.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.128 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -64.65 -27.04 68.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.138 176.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 1.5 tmtp? -87.9 -46.28 9.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.881 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . 0.496 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.9 t -61.86 -60.36 2.83 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.898 -176.49 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 19.1 pt -109.06 -34.82 2.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.616 -0.265 . . . . 0.0 111.683 -176.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 135.72 -39.87 1.61 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.052 -1.071 . . . . 0.0 113.145 177.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 29.5 m -79.13 147.32 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.962 0.41 . . . . 0.0 110.865 -177.251 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.71 42.32 1.1 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.448 0.642 . . . . 0.0 110.318 -179.063 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' 1' ' 36' ' ' TYR . . . -116.07 108.22 15.93 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.896 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -171.86 131.19 2.1 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.947 -177.448 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -125.93 166.17 17.41 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.846 0.355 . . . . 0.0 111.147 -173.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.44 91.93 6.05 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.964 -175.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.05 118.88 53.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.94 177.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 57.55 27.77 14.6 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.766 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.12 11.77 84.02 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.337 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . 0.564 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 10.5 mpt_? -116.19 165.8 12.75 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.061 0.458 . . . . 0.0 110.612 178.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 92.0 m -104.22 106.38 16.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.172 -176.472 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . 0.476 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 2.7 p -97.35 113.15 31.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.38 0.61 . . . . 0.0 110.159 174.65 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.9 m -85.85 145.6 27.12 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.04 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . 0.425 ' HB2' ' HB1' ' 1' ' 25' ' ' ALA . 27.5 m-85 -119.77 79.66 23.84 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.086 -177.376 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo . . . . . 0 C--O 1.249 1.069 0 C-N-CA 122.715 2.276 . . . . 0.0 112.521 177.918 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 52.5 mt . . . . . 0 N--CA 1.456 -0.13 0 CA-C-O 120.784 0.326 . . . . 0.0 111.3 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . 0.422 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 38.0 mt-10 -77.82 114.97 17.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.023 172.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 58.7 p -100.84 154.02 19.0 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.847 -178.567 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -81.73 48.77 1.24 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.098 0.475 . . . . 0.0 110.751 -178.721 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . 0.419 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 93.1 mttt -119.57 166.49 13.09 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . 0.527 ' O ' ' HD3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -94.46 144.73 25.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.7 178.705 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 48.0 m -69.86 163.35 26.09 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.287 -176.116 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -107.18 36.15 2.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.336 0.589 . . . . 0.0 110.546 -175.236 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.81 82.02 1.53 Allowed Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.224 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.8 -40.85 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.595 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 41.1 t -142.49 -176.04 4.69 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -142.3 28.72 1.66 Allowed 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.513 0.673 . . . . 0.0 109.377 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.37 -36.06 79.18 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.151 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 7.9 p -63.76 -41.68 97.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.161 0.505 . . . . 0.0 110.645 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . 0.461 ' O ' HG23 ' 1' ' 20' ' ' VAL . 54.0 t -66.72 -47.07 84.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.574 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -60.04 -30.9 69.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.326 178.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 79.1 ttt180 -67.43 -21.16 65.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.04 0.447 . . . . 0.0 110.5 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -95.0 -33.61 12.66 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.088 0.471 . . . . 0.0 110.223 177.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' 1' ' 16' ' ' VAL . 63.3 t -72.39 -67.97 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.284 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . 0.508 HG13 ' H ' ' 1' ' 23' ' ' VAL . 43.8 pt -97.86 -12.96 8.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.754 0.311 . . . . 0.0 111.501 -176.088 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.56 4.95 63.59 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.963 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . 0.508 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -121.41 146.41 26.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.45 38.9 1.23 Allowed 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.115 0.483 . . . . 0.0 110.956 -175.017 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -109.98 113.34 25.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.621 176.008 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -168.51 162.8 36.59 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.21 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 55.6 mtmt -141.06 175.29 9.74 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 18.0 t -105.9 111.42 24.06 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.05 177.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 58.9 mt -118.29 112.13 36.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.787 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 59.39 29.23 18.77 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.425 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.74 85.6 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.317 -178.344 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 33.4 mmt180 -114.27 162.3 16.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.036 0.446 . . . . 0.0 110.801 179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 63.6 m -98.71 109.76 22.46 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.058 -173.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' 1' ' 3' ' ' GLU . 7.3 p -97.28 122.26 48.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.031 0.443 . . . . 0.0 110.087 176.38 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 68.3 m -101.07 140.0 35.98 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.614 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -116.04 98.51 51.33 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.788 -179.023 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 122.65 2.233 . . . . 0.0 112.203 177.806 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 46.7 mt . . . . . 0 N--CA 1.453 -0.282 0 CA-C-O 120.815 0.341 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . 0.492 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 47.4 mt-10 -74.38 100.66 3.85 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.167 0.508 . . . . 0.0 110.273 174.158 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 73.4 p -90.05 168.07 12.27 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.091 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -87.89 13.94 9.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.377 0.608 . . . . 0.0 110.009 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -73.58 148.45 42.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.775 176.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . 0.492 ' HD2' ' N ' ' 1' ' 7' ' ' LYS . 12.7 mptt -95.19 145.85 24.74 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.585 -178.322 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . 0.669 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 12.8 m -59.42 153.56 18.95 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.735 -175.646 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -135.05 108.78 8.01 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.903 -177.494 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 76.88 16.95 80.33 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.906 -178.291 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.8 1.01 63.76 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.557 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 96.6 p -150.96 -179.42 7.28 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.757 0.313 . . . . 0.0 110.747 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . 0.669 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 92.5 m -133.74 25.15 4.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.009 0.433 . . . . 0.0 110.908 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.27 75.86 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.628 179.039 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -73.4 -29.54 62.67 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.414 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 88.3 t -63.69 -56.28 17.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.2 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.478 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 95.8 m -66.62 -22.35 66.12 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.367 -178.642 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -63.54 -24.33 67.77 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.07 0.462 . . . . 0.0 110.228 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -96.17 -35.18 11.4 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.375 176.734 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 68.4 t -70.44 -64.32 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.48 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . 0.44 HG13 ' H ' ' 1' ' 23' ' ' VAL . 40.1 pt -97.9 -30.2 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.756 0.312 . . . . 0.0 111.158 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.46 -32.45 4.3 Favored Glycine 0 CA--C 1.508 -0.372 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.535 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . 0.44 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.0 t -89.69 147.65 5.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.815 0.341 . . . . 0.0 110.154 -178.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.2 48.42 1.5 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.227 0.536 . . . . 0.0 111.225 -175.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -124.62 112.47 16.84 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.054 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . 0.531 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.09 125.14 1.3 Allowed Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.041 -177.333 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 56.9 mtpt -107.66 165.71 11.22 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.945 0.402 . . . . 0.0 110.719 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.4 t -100.75 100.17 10.81 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.721 -177.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 67.5 mt -109.18 107.39 22.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.556 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 57.01 32.06 21.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.401 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . 0.404 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 87.6 -1.15 85.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.632 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 11.2 mpt_? -105.56 157.47 17.37 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.952 0.406 . . . . 0.0 110.62 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 90.3 m -100.47 110.34 22.52 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.591 -175.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . 0.531 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -92.96 107.85 19.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.698 0.761 . . . . 0.0 110.017 175.317 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 66.4 m -85.56 139.22 31.63 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.564 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -117.84 101.76 51.78 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.343 178.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo . . . . . 0 C--O 1.248 1.003 0 C-N-CA 122.641 2.227 . . . . 0.0 112.437 179.835 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.0 mt . . . . . 0 N--CA 1.456 -0.15 0 CA-C-O 120.566 0.222 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 33.5 mt-10 -74.04 90.39 1.99 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.099 0.476 . . . . 0.0 110.293 173.169 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 69.2 p -75.75 156.15 34.89 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.265 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -83.3 37.35 0.56 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.761 0.791 . . . . 0.0 110.314 -178.652 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -111.42 152.98 26.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.509 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . 0.413 ' HA ' ' O ' ' 1' ' 31' ' ' GLY . 0.8 OUTLIER -93.64 138.46 31.85 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.795 0.331 . . . . 0.0 110.675 -179.206 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . 0.581 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 1.5 p -57.45 148.39 23.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.506 -177.46 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -91.02 66.6 5.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.408 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 78.8 45.92 8.92 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.463 178.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 118.43 -69.04 0.33 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.525 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 15.2 m -109.15 176.08 5.22 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.938 0.399 . . . . 0.0 110.689 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . 0.581 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 83.1 m -124.02 30.51 6.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.621 -178.322 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 -50.03 75.43 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.647 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.9 m -67.52 -39.15 85.08 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.053 179.393 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . 0.45 ' O ' HG23 ' 1' ' 20' ' ' VAL . 59.1 t -61.8 -55.91 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.783 -178.263 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 74.6 m -67.02 -26.69 66.9 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.07 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -64.87 -30.44 71.44 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.108 0.48 . . . . 0.0 110.237 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -83.58 -32.83 25.59 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.504 178.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . 0.45 HG23 ' O ' ' 1' ' 16' ' ' VAL . 60.6 t -81.78 -64.59 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.807 -176.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . 0.511 HG13 ' H ' ' 1' ' 23' ' ' VAL . 45.4 pt -100.05 -9.71 8.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.63 -175.522 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.29 2.68 70.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.904 177.106 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . 0.511 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -116.73 143.48 26.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.15 39.64 1.08 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.474 0.655 . . . . 0.0 111.222 -175.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -115.33 109.69 18.29 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.625 175.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -165.32 129.77 2.03 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.047 -176.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -118.98 169.27 10.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' 1' ' 32' ' ' ARG . 11.7 t -106.25 116.72 32.42 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-O 120.969 0.414 . . . . 0.0 110.611 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 75.8 mt -116.42 105.29 18.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.015 177.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 86.3 m-20 55.63 39.24 30.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.318 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 85.67 4.04 85.63 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.898 178.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . 0.483 ' O ' ' HA ' ' 1' ' 28' ' ' CYS . 10.6 mpt_? -107.75 158.82 16.97 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.858 0.361 . . . . 0.0 110.731 178.597 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . 0.469 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 21.2 m -103.44 106.39 16.89 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.366 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . 0.449 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 6.0 p -88.65 104.65 14.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.706 0.765 . . . . 0.0 110.011 175.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 72.2 m -83.11 136.61 34.4 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -114.83 100.23 53.14 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.471 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 C--O 1.249 1.041 0 C-N-CA 123.03 2.487 . . . . 0.0 111.337 174.854 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.8 mt . . . . . 0 N--CA 1.455 -0.182 0 CA-C-O 120.561 0.219 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.15 115.06 13.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.96 0.41 . . . . 0.0 110.122 173.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 50.9 p -105.16 158.67 16.42 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.348 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -87.17 53.18 2.73 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.617 0.722 . . . . 0.0 109.738 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -128.07 157.96 39.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.159 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 32.4 mttp -86.69 147.77 25.73 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.872 -177.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -89.59 171.12 9.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.892 -179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 16.1 mp0 -95.44 26.99 3.56 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.913 179.428 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 88.27 91.11 1.09 Allowed Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.829 -177.572 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.29 -47.44 3.09 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.679 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 48.9 m -127.31 172.36 10.68 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.149 0.499 . . . . 0.0 111.464 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . 0.858 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 49.2 t -138.47 37.56 2.25 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.207 -179.086 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.39 -46.85 85.58 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.956 -175.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 13.1 p -71.84 -39.86 69.44 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -174.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . 0.858 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 76.4 t -63.83 -54.95 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.59 0.233 . . . . 0.0 110.519 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 94.0 m -58.34 -34.0 70.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.79 178.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 51.1 ttp180 -64.84 -29.57 70.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.931 0.396 . . . . 0.0 110.706 178.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -86.49 -40.0 15.71 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.222 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . 0.479 HG23 ' O ' ' 1' ' 16' ' ' VAL . 59.3 t -68.43 -68.13 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.45 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 32.2 pt -101.48 -32.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.813 -174.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 134.46 -41.87 1.41 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.019 -1.086 . . . . 0.0 113.56 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.9 m -78.35 148.03 6.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.989 0.394 . . . . 0.0 110.952 -176.556 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -96.32 33.3 1.8 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.399 0.619 . . . . 0.0 110.204 179.354 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -107.0 110.63 22.83 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.528 175.46 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -163.51 141.28 7.02 Favored Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.669 -176.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -122.36 175.87 6.19 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.823 0.344 . . . . 0.0 110.279 -177.086 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 19.2 t -115.91 109.5 17.69 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.834 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 74.3 mt -107.31 108.02 24.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.072 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 56.77 40.35 29.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.546 177.422 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.24 1.19 90.33 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.617 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . 0.479 ' HA ' ' HE ' ' 1' ' 32' ' ' ARG . 1.1 mmp_? -105.67 165.27 11.29 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.971 0.415 . . . . 0.0 110.424 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 15.1 t -101.88 129.53 48.15 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.545 -176.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 p -120.92 115.78 47.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.255 0.55 . . . . 0.0 110.286 175.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 80.3 m -88.48 141.1 28.81 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.107 -177.667 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -120.05 88.43 40.89 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.213 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo . . . . . 0 C--O 1.248 1.016 0 C-N-CA 122.788 2.325 . . . . 0.0 112.51 -178.562 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 55.2 mt . . . . . 0 N--CA 1.452 -0.371 0 CA-C-O 121.266 0.555 . . . . 0.0 110.782 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . 0.443 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 43.1 mt-10 -70.77 132.94 46.09 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.167 173.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 66.8 p -128.04 168.02 15.9 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.038 0.447 . . . . 0.0 110.373 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -85.98 -3.96 59.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.327 0.584 . . . . 0.0 110.391 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 27.7 mtpp -65.51 150.54 48.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.744 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -88.08 144.41 26.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.892 -174.113 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 5.0 m -68.5 168.57 12.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.114 -174.012 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 27.4 mm-40 -124.0 64.32 1.06 Allowed 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.784 -177.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.31 39.51 6.35 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.756 177.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.5 -6.05 74.4 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.248 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 87.9 p -133.76 -175.06 3.7 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . 0.873 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 25.6 t -143.73 29.26 1.39 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.362 0.601 . . . . 0.0 109.779 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.62 -47.24 86.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.383 -176.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.02 -38.17 79.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.595 -177.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . 0.873 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 54.2 t -69.9 -50.85 45.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.885 0.374 . . . . 0.0 110.593 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 83.9 m -60.77 -31.2 70.56 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.975 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . 0.423 ' O ' ' HA2' ' 1' ' 22' ' ' GLY . 49.5 ttp180 -64.46 -25.16 67.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.109 0.481 . . . . 0.0 110.161 178.548 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -85.49 -44.58 12.58 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.403 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.9 t -69.38 -66.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.925 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . 0.512 HG13 ' H ' ' 1' ' 23' ' ' VAL . 38.0 pt -94.28 -22.86 5.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.701 0.286 . . . . 0.0 111.5 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' 1' ' 18' ' ' ARG . . . 99.77 10.79 45.68 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.439 -0.886 . . . . 0.0 112.616 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . 0.512 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.9 t -126.13 146.71 31.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.174 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.97 38.85 1.07 Allowed 'General case' 0 C--N 1.314 -0.976 0 CA-C-O 121.516 0.674 . . . . 0.0 110.597 -176.288 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -111.24 108.54 18.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-N 115.267 -0.878 . . . . 0.0 109.536 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.3 140.02 6.1 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.03 -175.548 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . 0.438 ' HE2' ' CE1' ' 1' ' 36' ' ' TYR . 52.0 mtmt -123.61 177.5 5.65 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.837 0.351 . . . . 0.0 110.436 -177.152 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 22.2 t -113.96 115.69 28.05 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.597 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 79.4 mt -112.12 101.85 13.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.249 177.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 53.98 43.07 31.34 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.62 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.4 9.62 85.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.851 178.135 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 50.1 mmt-85 -118.76 150.71 39.34 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.0 110.179 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 10.3 t -85.31 144.31 28.15 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.067 -176.218 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . 0.461 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 6.8 p -135.19 116.77 20.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.287 0.565 . . . . 0.0 110.168 173.711 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . 0.404 ' HB3' HD13 ' 1' ' 21' ' ' ILE . 99.8 m -95.14 138.3 33.03 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.624 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . 0.438 ' CE1' ' HE2' ' 1' ' 27' ' ' LYS . 19.4 m-85 -116.2 98.34 51.17 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.247 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo . . . . . 0 C--O 1.25 1.122 0 C-N-CA 122.933 2.422 . . . . 0.0 111.938 177.654 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 51.4 mt . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.766 0.317 . . . . 0.0 111.278 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -71.08 93.46 1.03 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.886 0.375 . . . . 0.0 110.644 175.084 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 46.7 p -81.68 149.77 28.35 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.232 177.253 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -82.29 53.95 2.42 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.368 0.604 . . . . 0.0 110.438 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -109.69 146.07 35.47 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.482 178.547 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 45.8 mtpt -79.49 133.45 36.51 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 172.326 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . 0.642 ' HA ' ' SG ' ' 1' ' 33' ' ' CYS . 3.8 m -56.06 139.68 46.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.156 0.503 . . . . 0.0 110.69 -177.173 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 28.9 tt0 -89.23 56.58 3.71 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.693 -174.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 103.38 -71.53 0.28 Allowed Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.735 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -132.78 -30.2 0.5 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.25 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 5.4 m -132.75 -178.75 5.08 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . 0.494 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 1.1 m -134.09 35.59 3.28 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.271 174.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.14 -48.74 80.21 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.014 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.6 m -68.9 -32.84 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.198 0.523 . . . . 0.0 110.29 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 55.4 t -62.96 -53.76 42.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.441 177.241 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 82.5 m -66.38 -24.45 66.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.43 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -63.23 -28.46 70.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.09 0.472 . . . . 0.0 110.064 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -89.41 -36.59 15.38 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.28 178.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.1 t -73.63 -61.37 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.819 -177.136 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 44.4 pt -106.98 -5.96 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -175.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.72 11.12 71.54 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.542 -0.837 . . . . 0.0 113.176 176.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -122.15 143.89 33.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.463 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.74 46.07 1.22 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.516 0.674 . . . . 0.0 110.886 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . 0.483 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -129.23 114.14 15.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.739 175.672 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -157.65 120.21 0.96 Allowed Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.523 -177.023 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -108.22 157.2 18.54 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 -174.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 44.5 t -101.14 122.95 44.51 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.827 -177.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 54.6 mt -126.89 103.22 10.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.298 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 52.81 44.47 30.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.593 -0.731 . . . . 0.0 112.153 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.55 -19.93 51.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.24 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -100.37 163.79 12.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -178.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . 0.642 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 76.4 m -118.94 124.93 48.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.195 0.522 . . . . 0.0 111.765 -175.27 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . 0.401 HG13 ' HE2' ' 1' ' 36' ' ' TYR . 2.7 p -102.96 121.3 53.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.285 177.517 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 73.3 m -90.02 138.97 31.07 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.594 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . 0.483 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 70.1 m-85 -118.16 109.77 40.4 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.115 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo . . . . . 0 C--O 1.249 1.043 0 C-N-CA 122.837 2.358 . . . . 0.0 112.563 178.815 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . 0.407 ' HB ' ' HB2' ' 1' ' 35' ' ' CYS . 67.5 mt . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.976 0.417 . . . . 0.0 111.376 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -70.78 120.09 15.88 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.805 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 76.2 p -113.47 161.98 16.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.358 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -87.23 13.85 8.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 110.88 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -85.29 156.1 21.07 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.706 -176.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt -80.41 146.95 31.21 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.773 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 m -71.76 160.93 31.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.414 -175.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 17.6 tp60 -106.41 68.43 0.76 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.73 -177.091 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.64 45.28 54.03 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.736 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.54 -30.36 9.96 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.69 178.382 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 94.4 p -114.67 -161.98 0.8 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.431 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . 0.866 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 30.2 t -144.93 28.49 1.25 Allowed 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.692 0.758 . . . . 0.0 109.175 172.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.9 -61.65 2.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.112 -177.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.21 -20.35 63.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . 0.866 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 67.2 t -77.58 -58.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.741 0.305 . . . . 0.0 110.212 179.182 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 73.7 m -59.73 -30.33 68.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.354 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -56.51 -35.11 67.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.853 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -91.41 -35.93 14.09 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.75 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.6 t -71.48 -61.64 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.609 -177.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . 0.526 HG13 ' H ' ' 1' ' 23' ' ' VAL . 39.5 pt -102.33 -30.02 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.786 -0.366 . . . . 0.0 111.709 -176.025 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.04 -25.57 6.36 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.056 178.183 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . 0.526 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.2 t -95.96 148.29 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.011 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.52 28.31 3.83 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.073 0.464 . . . . 0.0 111.367 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . 0.524 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -105.95 120.08 40.83 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.728 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -167.39 139.6 5.81 Favored Glycine 0 N--CA 1.441 -1.026 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.801 -178.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 60.8 mtpt -118.31 173.02 7.05 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.659 0.266 . . . . 0.0 110.296 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 38.9 t -115.9 127.1 54.74 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.037 -177.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 57.0 mt -124.8 104.44 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.192 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 58.77 34.33 23.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.14 178.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.08 12.83 72.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.36 179.162 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 12.9 mmt85 -120.66 153.76 36.44 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.8 0.333 . . . . 0.0 110.175 176.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 5.8 t -94.41 142.01 27.91 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.184 0.516 . . . . 0.0 111.576 -172.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.16 115.64 27.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.895 172.39 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . 0.407 ' HB2' ' HB ' ' 1' ' 2' ' ' ILE . 75.6 m -85.09 142.0 29.85 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.065 -177.28 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 46.3 m-85 -122.16 94.14 48.16 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.01 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo . . . . . 0 C--O 1.25 1.105 0 C-N-CA 123.185 2.59 . . . . 0.0 111.589 175.805 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 33.8 mt . . . . . 0 N--CA 1.453 -0.309 0 CA-C-O 120.652 0.263 . . . . 0.0 110.728 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . 0.444 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 9.2 mp0 -76.81 104.71 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 174.538 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 57.8 p -94.51 165.74 12.39 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.473 -0.331 . . . . 0.0 110.537 -178.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -91.63 28.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.112 0.482 . . . . 0.0 111.204 -178.397 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 31.5 mtmm -93.68 149.62 21.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.275 176.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -84.96 143.11 29.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.718 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . 0.693 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 3.6 m -57.56 152.26 15.27 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.751 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 58.7 tp60 -118.05 69.59 0.79 Allowed 'General case' 0 N--CA 1.451 -0.411 0 CA-C-O 121.224 0.535 . . . . 0.0 110.118 -177.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.83 59.97 1.64 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 177.275 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.51 -34.98 2.86 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.073 176.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 50.1 m -133.22 -179.77 5.71 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.877 0.37 . . . . 0.0 110.506 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . 0.693 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.0 m -132.14 30.2 4.26 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.937 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -60.66 -48.79 80.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.272 -177.82 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . 0.497 ' HA ' ' HE ' ' 1' ' 18' ' ' ARG . 25.3 m -75.04 -25.92 59.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.957 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . 0.554 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.0 t -62.07 -56.58 16.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.104 0.478 . . . . 0.0 109.798 175.097 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 66.7 m -66.88 -24.64 66.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.144 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . 0.497 ' HE ' ' HA ' ' 1' ' 15' ' ' SER . 10.1 ttm-85 -62.92 -30.73 71.77 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-O 121.225 0.536 . . . . 0.0 109.77 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -87.95 -38.79 15.26 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.778 178.609 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . 0.554 HG23 ' O ' ' 1' ' 16' ' ' VAL . 43.8 t -68.45 -66.02 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.257 -177.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 31.2 pt -109.65 -10.46 11.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.83 0.348 . . . . 0.0 111.735 -175.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 109.48 -32.87 6.46 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.345 -0.931 . . . . 0.0 113.381 174.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . 0.473 HG21 ' O ' ' 1' ' 36' ' ' TYR . 14.6 m -81.76 144.79 9.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.997 0.427 . . . . 0.0 110.774 -177.081 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.54 44.23 1.17 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.483 0.659 . . . . 0.0 110.329 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . 0.432 ' HB1' ' HB2' ' 1' ' 36' ' ' TYR . . . -117.68 106.19 12.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.817 177.183 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . 0.664 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -163.36 126.2 1.5 Allowed Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.037 -176.383 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -112.16 164.98 12.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.81 0.338 . . . . 0.0 111.103 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.7 t -102.89 93.91 5.3 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.094 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 60.0 mt -104.17 105.74 19.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.309 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 60.08 37.48 21.01 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 123.293 0.371 . . . . 0.0 111.595 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.06 26.49 70.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.883 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -126.05 156.32 40.15 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 62.9 m -105.87 110.03 22.18 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.001 0.429 . . . . 0.0 111.132 -177.364 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . 0.664 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -98.88 119.45 46.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.275 176.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.0 m -95.85 138.51 33.39 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.619 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . 0.473 ' O ' HG21 ' 1' ' 23' ' ' VAL . 37.7 m-85 -114.0 100.82 53.21 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.857 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo . . . . . 0 C--O 1.251 1.175 0 C-N-CA 122.832 2.355 . . . . 0.0 112.414 178.496 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 44.7 mm . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.683 0.278 . . . . 0.0 111.196 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -75.5 99.24 4.16 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 172.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 82.4 p -90.08 154.91 19.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.638 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 5' ' ' ASN . . . . . 0.472 ' HA ' ' HD2' ' 1' ' 32' ' ' ARG . 86.2 m-20 -81.14 31.22 0.32 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.986 0.422 . . . . 0.0 111.414 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -93.8 139.41 30.89 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.831 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 7' ' ' LYS . . . . . 0.558 ' HD3' ' H ' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -74.1 146.64 43.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.095 177.508 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' 1' 1 ' 8' ' ' CYS . . . . . 0.742 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.2 m -61.98 153.07 30.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.137 -176.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -98.25 76.72 2.35 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.297 0.57 . . . . 0.0 109.483 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -70.65 3.1 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.231 -178.135 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.63 -23.89 0.5 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.981 -179.216 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 47.5 m -141.2 -177.94 5.35 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 122.634 -0.333 . . . . 0.0 110.158 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 13' ' ' CYS . . . . . 0.742 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 72.7 m -131.43 25.04 4.81 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.093 0.473 . . . . 0.0 110.803 -178.52 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.281 -178.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 20.4 m -70.78 -31.24 67.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.707 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 16' ' ' VAL . . . . . 0.475 ' O ' HG23 ' 1' ' 20' ' ' VAL . 77.5 t -62.4 -53.4 47.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.05 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 79.1 m -65.82 -29.98 70.54 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.918 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.4 ttt180 -65.5 -31.37 72.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.147 0.499 . . . . 0.0 110.268 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -81.99 -40.16 22.57 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.719 177.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 20' ' ' VAL . . . . . 0.475 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.4 t -70.77 -70.28 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.535 -178.596 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 28.8 pt -100.21 -29.23 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -174.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.1 -37.03 2.37 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.072 -1.061 . . . . 0.0 113.378 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.4 m -74.78 145.91 10.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 117.002 0.401 . . . . 0.0 110.673 -178.071 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -95.64 40.65 1.11 Allowed 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.396 0.617 . . . . 0.0 110.484 -178.261 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -119.18 106.77 12.69 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.518 175.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 26' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -157.43 120.52 0.99 Allowed Glycine 0 N--CA 1.444 -0.826 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.305 -177.588 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 57.0 mtpt -111.17 159.07 18.21 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 120.983 0.42 . . . . 0.0 111.14 -174.048 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 53.8 t -97.37 114.78 26.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.601 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 69.9 mt -123.09 103.13 12.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.429 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 55.12 36.41 26.92 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.801 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 83.59 22.3 56.38 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.347 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 32' ' ' ARG . . . . . 0.472 ' HD2' ' HA ' ' 1' ' 5' ' ' ASN . 36.6 mmt180 -124.28 156.21 37.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.699 0.285 . . . . 0.0 110.408 177.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 88.8 m -108.12 107.45 18.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.227 -177.345 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 34' ' ' VAL . . . . . 0.465 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 3.6 p -94.38 111.82 25.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.43 0.633 . . . . 0.0 110.233 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.11 139.58 30.43 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -118.43 90.02 37.83 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.001 -178.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo . . . . . 0 C--O 1.248 1.017 0 C-N-CA 122.641 2.227 . . . . 0.0 111.833 176.267 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.815 0 CA-C-O 120.635 0.255 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 39.3 mm -95.62 91.6 2.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.176 0.513 . . . . 0.0 110.525 -177.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . 0.421 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 29.7 mt-10 -81.75 92.96 6.72 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.756 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 75.5 p -86.4 145.62 26.79 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.11 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -83.64 52.47 2.26 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.737 0.779 . . . . 0.0 110.252 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . 0.564 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 67.4 mttm -105.88 157.62 17.35 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.32 177.458 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . 0.536 ' O ' ' HD2' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -82.15 144.5 30.7 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.716 0.293 . . . . 0.0 110.262 177.984 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . 0.641 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.7 m -67.67 150.09 49.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.71 -177.55 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -96.47 72.26 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 94.97 -77.96 0.88 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.567 -177.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.3 -15.27 0.9 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 16.2 m -144.36 -177.61 5.56 Favored 'General case' 0 C--N 1.324 -0.519 0 O-C-N 122.591 -0.358 . . . . 0.0 110.131 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . 0.641 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.9 m -134.78 27.26 3.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.636 -177.439 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.31 -47.22 83.15 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.425 -178.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 18.6 t -70.61 -30.71 67.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.131 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . 0.496 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.7 t -62.71 -54.07 38.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.223 175.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.71 -28.04 68.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.128 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -64.65 -27.04 68.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.138 176.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 1.5 tmtp? -87.9 -46.28 9.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.881 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . 0.496 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.9 t -61.86 -60.36 2.83 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.898 -176.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 19.1 pt -109.06 -34.82 2.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.616 -0.265 . . . . 0.0 111.683 -176.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 135.72 -39.87 1.61 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.052 -1.071 . . . . 0.0 113.145 177.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 29.5 m -79.13 147.32 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.962 0.41 . . . . 0.0 110.865 -177.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.71 42.32 1.1 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.448 0.642 . . . . 0.0 110.318 -179.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' 1' ' 36' ' ' TYR . . . -116.07 108.22 15.93 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.896 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -171.86 131.19 2.1 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.947 -177.448 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -125.93 166.17 17.41 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.846 0.355 . . . . 0.0 111.147 -173.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.44 91.93 6.05 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.964 -175.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.05 118.88 53.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.94 177.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 57.55 27.77 14.6 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.766 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.12 11.77 84.02 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.337 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . 0.564 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 10.5 mpt_? -116.19 165.8 12.75 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.061 0.458 . . . . 0.0 110.612 178.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 92.0 m -104.22 106.38 16.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.172 -176.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . 0.476 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 2.7 p -97.35 113.15 31.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.38 0.61 . . . . 0.0 110.159 174.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.9 m -85.85 145.6 27.12 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.04 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . 0.425 ' HB2' ' HB1' ' 1' ' 25' ' ' ALA . 27.5 m-85 -119.77 79.66 23.84 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.086 -177.376 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo . . . . . 0 C--O 1.249 1.069 0 C-N-CA 122.715 2.276 . . . . 0.0 112.521 177.918 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 52.5 mt -107.13 95.35 3.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 120.784 0.326 . . . . 0.0 111.3 -175.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . 0.422 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 38.0 mt-10 -77.82 114.97 17.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.023 172.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 58.7 p -100.84 154.02 19.0 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.847 -178.567 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -81.73 48.77 1.24 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.098 0.475 . . . . 0.0 110.751 -178.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . 0.419 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 93.1 mttt -119.57 166.49 13.09 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . 0.527 ' O ' ' HD3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -94.46 144.73 25.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.7 178.705 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 48.0 m -69.86 163.35 26.09 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.287 -176.116 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -107.18 36.15 2.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.336 0.589 . . . . 0.0 110.546 -175.236 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.81 82.02 1.53 Allowed Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.224 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.8 -40.85 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.595 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 41.1 t -142.49 -176.04 4.69 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -142.3 28.72 1.66 Allowed 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.513 0.673 . . . . 0.0 109.377 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.37 -36.06 79.18 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.151 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 7.9 p -63.76 -41.68 97.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.161 0.505 . . . . 0.0 110.645 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . 0.461 ' O ' HG23 ' 1' ' 20' ' ' VAL . 54.0 t -66.72 -47.07 84.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.574 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -60.04 -30.9 69.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.326 178.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 79.1 ttt180 -67.43 -21.16 65.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.04 0.447 . . . . 0.0 110.5 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -95.0 -33.61 12.66 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.088 0.471 . . . . 0.0 110.223 177.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' 1' ' 16' ' ' VAL . 63.3 t -72.39 -67.97 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.284 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . 0.508 HG13 ' H ' ' 1' ' 23' ' ' VAL . 43.8 pt -97.86 -12.96 8.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.754 0.311 . . . . 0.0 111.501 -176.088 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.56 4.95 63.59 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.963 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . 0.508 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -121.41 146.41 26.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.45 38.9 1.23 Allowed 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.115 0.483 . . . . 0.0 110.956 -175.017 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -109.98 113.34 25.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.621 176.008 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -168.51 162.8 36.59 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.21 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 55.6 mtmt -141.06 175.29 9.74 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 18.0 t -105.9 111.42 24.06 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.05 177.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 58.9 mt -118.29 112.13 36.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.787 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 59.39 29.23 18.77 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.425 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.74 85.6 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.317 -178.344 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 33.4 mmt180 -114.27 162.3 16.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.036 0.446 . . . . 0.0 110.801 179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 63.6 m -98.71 109.76 22.46 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.058 -173.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' 1' ' 3' ' ' GLU . 7.3 p -97.28 122.26 48.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.031 0.443 . . . . 0.0 110.087 176.38 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 68.3 m -101.07 140.0 35.98 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.614 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -116.04 98.51 51.33 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.788 -179.023 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 122.65 2.233 . . . . 0.0 112.203 177.806 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 46.7 mt -124.7 91.84 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.815 0.341 . . . . 0.0 111.079 -179.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . 0.492 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 47.4 mt-10 -74.38 100.66 3.85 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.167 0.508 . . . . 0.0 110.273 174.158 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 73.4 p -90.05 168.07 12.27 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.091 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -87.89 13.94 9.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.377 0.608 . . . . 0.0 110.009 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -73.58 148.45 42.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.775 176.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . 0.492 ' HD2' ' N ' ' 1' ' 7' ' ' LYS . 12.7 mptt -95.19 145.85 24.74 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.585 -178.322 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . 0.669 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 12.8 m -59.42 153.56 18.95 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.735 -175.646 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -135.05 108.78 8.01 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.903 -177.494 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 76.88 16.95 80.33 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.906 -178.291 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.8 1.01 63.76 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.557 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 96.6 p -150.96 -179.42 7.28 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.757 0.313 . . . . 0.0 110.747 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . 0.669 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 92.5 m -133.74 25.15 4.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.009 0.433 . . . . 0.0 110.908 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.27 75.86 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.628 179.039 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -73.4 -29.54 62.67 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.414 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 88.3 t -63.69 -56.28 17.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.2 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.478 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 95.8 m -66.62 -22.35 66.12 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.367 -178.642 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -63.54 -24.33 67.77 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.07 0.462 . . . . 0.0 110.228 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -96.17 -35.18 11.4 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.375 176.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 68.4 t -70.44 -64.32 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.48 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . 0.44 HG13 ' H ' ' 1' ' 23' ' ' VAL . 40.1 pt -97.9 -30.2 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.756 0.312 . . . . 0.0 111.158 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.46 -32.45 4.3 Favored Glycine 0 CA--C 1.508 -0.372 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.535 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . 0.44 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.0 t -89.69 147.65 5.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.815 0.341 . . . . 0.0 110.154 -178.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.2 48.42 1.5 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.227 0.536 . . . . 0.0 111.225 -175.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -124.62 112.47 16.84 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.054 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . 0.531 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.09 125.14 1.3 Allowed Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.041 -177.333 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 56.9 mtpt -107.66 165.71 11.22 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.945 0.402 . . . . 0.0 110.719 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.4 t -100.75 100.17 10.81 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.721 -177.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 67.5 mt -109.18 107.39 22.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.556 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 57.01 32.06 21.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.401 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . 0.404 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 87.6 -1.15 85.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.632 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 11.2 mpt_? -105.56 157.47 17.37 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.952 0.406 . . . . 0.0 110.62 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 90.3 m -100.47 110.34 22.52 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.591 -175.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . 0.531 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -92.96 107.85 19.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.698 0.761 . . . . 0.0 110.017 175.317 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 66.4 m -85.56 139.22 31.63 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.564 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -117.84 101.76 51.78 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.343 178.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo . . . . . 0 C--O 1.248 1.003 0 C-N-CA 122.641 2.227 . . . . 0.0 112.437 179.835 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.863 0 N-CA-C 110.324 -0.25 . . . . 0.0 110.324 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.0 mt -124.23 98.87 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.215 -178.255 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 33.5 mt-10 -74.04 90.39 1.99 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.099 0.476 . . . . 0.0 110.293 173.169 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 69.2 p -75.75 156.15 34.89 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.265 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -83.3 37.35 0.56 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.761 0.791 . . . . 0.0 110.314 -178.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -111.42 152.98 26.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.509 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . 0.413 ' HA ' ' O ' ' 1' ' 31' ' ' GLY . 0.8 OUTLIER -93.64 138.46 31.85 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.795 0.331 . . . . 0.0 110.675 -179.206 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . 0.581 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 1.5 p -57.45 148.39 23.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.506 -177.46 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -91.02 66.6 5.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.408 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 78.8 45.92 8.92 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.463 178.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 118.43 -69.04 0.33 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.525 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 15.2 m -109.15 176.08 5.22 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.938 0.399 . . . . 0.0 110.689 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . 0.581 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 83.1 m -124.02 30.51 6.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.621 -178.322 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 -50.03 75.43 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.647 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.9 m -67.52 -39.15 85.08 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.053 179.393 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . 0.45 ' O ' HG23 ' 1' ' 20' ' ' VAL . 59.1 t -61.8 -55.91 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.783 -178.263 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 74.6 m -67.02 -26.69 66.9 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.07 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -64.87 -30.44 71.44 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.108 0.48 . . . . 0.0 110.237 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -83.58 -32.83 25.59 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.504 178.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . 0.45 HG23 ' O ' ' 1' ' 16' ' ' VAL . 60.6 t -81.78 -64.59 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.807 -176.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . 0.511 HG13 ' H ' ' 1' ' 23' ' ' VAL . 45.4 pt -100.05 -9.71 8.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.63 -175.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.29 2.68 70.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.904 177.106 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . 0.511 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -116.73 143.48 26.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.15 39.64 1.08 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.474 0.655 . . . . 0.0 111.222 -175.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -115.33 109.69 18.29 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.625 175.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -165.32 129.77 2.03 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.047 -176.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -118.98 169.27 10.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' 1' ' 32' ' ' ARG . 11.7 t -106.25 116.72 32.42 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-O 120.969 0.414 . . . . 0.0 110.611 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 75.8 mt -116.42 105.29 18.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.015 177.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 86.3 m-20 55.63 39.24 30.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.318 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 85.67 4.04 85.63 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.898 178.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . 0.483 ' O ' ' HA ' ' 1' ' 28' ' ' CYS . 10.6 mpt_? -107.75 158.82 16.97 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.858 0.361 . . . . 0.0 110.731 178.597 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . 0.469 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 21.2 m -103.44 106.39 16.89 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.366 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . 0.449 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 6.0 p -88.65 104.65 14.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.706 0.765 . . . . 0.0 110.011 175.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 72.2 m -83.11 136.61 34.4 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -114.83 100.23 53.14 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.471 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 C--O 1.249 1.041 0 C-N-CA 123.03 2.487 . . . . 0.0 111.337 174.854 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 120.725 0.297 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.8 mt -124.04 96.36 3.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.796 -179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.15 115.06 13.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.96 0.41 . . . . 0.0 110.122 173.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 50.9 p -105.16 158.67 16.42 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.348 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -87.17 53.18 2.73 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.617 0.722 . . . . 0.0 109.738 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -128.07 157.96 39.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.159 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 32.4 mttp -86.69 147.77 25.73 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.872 -177.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -89.59 171.12 9.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.892 -179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 16.1 mp0 -95.44 26.99 3.56 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.913 179.428 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 88.27 91.11 1.09 Allowed Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.829 -177.572 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.29 -47.44 3.09 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.679 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 48.9 m -127.31 172.36 10.68 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.149 0.499 . . . . 0.0 111.464 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . 0.858 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 49.2 t -138.47 37.56 2.25 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.207 -179.086 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.39 -46.85 85.58 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.956 -175.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 13.1 p -71.84 -39.86 69.44 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -174.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . 0.858 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 76.4 t -63.83 -54.95 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.59 0.233 . . . . 0.0 110.519 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 94.0 m -58.34 -34.0 70.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.79 178.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 51.1 ttp180 -64.84 -29.57 70.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.931 0.396 . . . . 0.0 110.706 178.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -86.49 -40.0 15.71 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.222 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . 0.479 HG23 ' O ' ' 1' ' 16' ' ' VAL . 59.3 t -68.43 -68.13 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.45 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 32.2 pt -101.48 -32.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.813 -174.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 134.46 -41.87 1.41 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.019 -1.086 . . . . 0.0 113.56 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.9 m -78.35 148.03 6.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.989 0.394 . . . . 0.0 110.952 -176.556 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -96.32 33.3 1.8 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.399 0.619 . . . . 0.0 110.204 179.354 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -107.0 110.63 22.83 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.528 175.46 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -163.51 141.28 7.02 Favored Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.669 -176.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -122.36 175.87 6.19 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.823 0.344 . . . . 0.0 110.279 -177.086 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 19.2 t -115.91 109.5 17.69 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.834 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 74.3 mt -107.31 108.02 24.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.072 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 56.77 40.35 29.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.546 177.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.24 1.19 90.33 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.617 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . 0.479 ' HA ' ' HE ' ' 1' ' 32' ' ' ARG . 1.1 mmp_? -105.67 165.27 11.29 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.971 0.415 . . . . 0.0 110.424 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 15.1 t -101.88 129.53 48.15 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.545 -176.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 p -120.92 115.78 47.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.255 0.55 . . . . 0.0 110.286 175.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 80.3 m -88.48 141.1 28.81 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.107 -177.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -120.05 88.43 40.89 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.213 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo . . . . . 0 C--O 1.248 1.016 0 C-N-CA 122.788 2.325 . . . . 0.0 112.51 -178.562 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . 0.527 ' HB2' ' CG2' ' 1' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.475 0.805 0 CA-C-O 120.64 0.257 . . . . 0.0 110.491 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 55.2 mt -89.01 90.7 3.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.266 0.555 . . . . 0.0 110.782 -177.019 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . 0.443 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 43.1 mt-10 -70.77 132.94 46.09 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.167 173.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 66.8 p -128.04 168.02 15.9 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.038 0.447 . . . . 0.0 110.373 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -85.98 -3.96 59.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.327 0.584 . . . . 0.0 110.391 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 27.7 mtpp -65.51 150.54 48.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.744 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -88.08 144.41 26.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.892 -174.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 5.0 m -68.5 168.57 12.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.114 -174.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 27.4 mm-40 -124.0 64.32 1.06 Allowed 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.784 -177.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.31 39.51 6.35 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.756 177.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.5 -6.05 74.4 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.248 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 87.9 p -133.76 -175.06 3.7 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . 0.873 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 25.6 t -143.73 29.26 1.39 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.362 0.601 . . . . 0.0 109.779 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.62 -47.24 86.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.383 -176.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.02 -38.17 79.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.595 -177.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . 0.873 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 54.2 t -69.9 -50.85 45.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.885 0.374 . . . . 0.0 110.593 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 83.9 m -60.77 -31.2 70.56 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.975 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . 0.423 ' O ' ' HA2' ' 1' ' 22' ' ' GLY . 49.5 ttp180 -64.46 -25.16 67.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.109 0.481 . . . . 0.0 110.161 178.548 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -85.49 -44.58 12.58 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.403 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.9 t -69.38 -66.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.925 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . 0.512 HG13 ' H ' ' 1' ' 23' ' ' VAL . 38.0 pt -94.28 -22.86 5.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.701 0.286 . . . . 0.0 111.5 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' 1' ' 18' ' ' ARG . . . 99.77 10.79 45.68 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.439 -0.886 . . . . 0.0 112.616 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . 0.512 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.9 t -126.13 146.71 31.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.174 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.97 38.85 1.07 Allowed 'General case' 0 C--N 1.314 -0.976 0 CA-C-O 121.516 0.674 . . . . 0.0 110.597 -176.288 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -111.24 108.54 18.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-N 115.267 -0.878 . . . . 0.0 109.536 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.3 140.02 6.1 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.03 -175.548 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . 0.438 ' HE2' ' CE1' ' 1' ' 36' ' ' TYR . 52.0 mtmt -123.61 177.5 5.65 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.837 0.351 . . . . 0.0 110.436 -177.152 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 22.2 t -113.96 115.69 28.05 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.597 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 79.4 mt -112.12 101.85 13.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.249 177.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 53.98 43.07 31.34 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.62 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.4 9.62 85.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.851 178.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 50.1 mmt-85 -118.76 150.71 39.34 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.0 110.179 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 10.3 t -85.31 144.31 28.15 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.067 -176.218 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . 0.527 ' CG2' ' HB2' ' 1' ' 1' ' ' PCA . 6.8 p -135.19 116.77 20.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.287 0.565 . . . . 0.0 110.168 173.711 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . 0.404 ' HB3' HD13 ' 1' ' 21' ' ' ILE . 99.8 m -95.14 138.3 33.03 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.624 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . 0.438 ' CE1' ' HE2' ' 1' ' 27' ' ' LYS . 19.4 m-85 -116.2 98.34 51.17 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.247 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo . . . . . 0 C--O 1.25 1.122 0 C-N-CA 122.933 2.422 . . . . 0.0 111.938 177.654 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.778 0 N-CA-C 110.386 -0.227 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 51.4 mt -96.46 95.28 4.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.766 0.317 . . . . 0.0 111.278 -175.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -71.08 93.46 1.03 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.886 0.375 . . . . 0.0 110.644 175.084 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 46.7 p -81.68 149.77 28.35 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.232 177.253 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -82.29 53.95 2.42 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.368 0.604 . . . . 0.0 110.438 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -109.69 146.07 35.47 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.482 178.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 45.8 mtpt -79.49 133.45 36.51 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 172.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . 0.642 ' HA ' ' SG ' ' 1' ' 33' ' ' CYS . 3.8 m -56.06 139.68 46.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.156 0.503 . . . . 0.0 110.69 -177.173 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 28.9 tt0 -89.23 56.58 3.71 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.693 -174.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 103.38 -71.53 0.28 Allowed Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.735 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -132.78 -30.2 0.5 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.25 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 5.4 m -132.75 -178.75 5.08 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . 0.494 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 1.1 m -134.09 35.59 3.28 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.271 174.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.14 -48.74 80.21 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.014 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.6 m -68.9 -32.84 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.198 0.523 . . . . 0.0 110.29 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 55.4 t -62.96 -53.76 42.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.441 177.241 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 82.5 m -66.38 -24.45 66.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.43 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -63.23 -28.46 70.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.09 0.472 . . . . 0.0 110.064 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -89.41 -36.59 15.38 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.28 178.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.1 t -73.63 -61.37 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.819 -177.136 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 44.4 pt -106.98 -5.96 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -175.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.72 11.12 71.54 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.542 -0.837 . . . . 0.0 113.176 176.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -122.15 143.89 33.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.463 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.74 46.07 1.22 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.516 0.674 . . . . 0.0 110.886 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . 0.483 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -129.23 114.14 15.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.739 175.672 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -157.65 120.21 0.96 Allowed Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.523 -177.023 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -108.22 157.2 18.54 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 -174.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 44.5 t -101.14 122.95 44.51 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.827 -177.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 54.6 mt -126.89 103.22 10.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.298 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 52.81 44.47 30.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.593 -0.731 . . . . 0.0 112.153 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.55 -19.93 51.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.24 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -100.37 163.79 12.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -178.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . 0.642 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 76.4 m -118.94 124.93 48.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.195 0.522 . . . . 0.0 111.765 -175.27 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . 0.401 HG13 ' HE2' ' 1' ' 36' ' ' TYR . 2.7 p -102.96 121.3 53.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.285 177.517 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 73.3 m -90.02 138.97 31.07 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.594 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . 0.483 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 70.1 m-85 -118.16 109.77 40.4 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.115 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo . . . . . 0 C--O 1.249 1.043 0 C-N-CA 122.837 2.358 . . . . 0.0 112.563 178.815 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 CA-C-O 120.796 0.331 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . 0.407 ' HB ' ' HB2' ' 1' ' 35' ' ' CYS . 67.5 mt -108.68 94.83 3.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.976 0.417 . . . . 0.0 111.376 -175.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -70.78 120.09 15.88 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.805 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 76.2 p -113.47 161.98 16.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.358 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -87.23 13.85 8.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 110.88 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -85.29 156.1 21.07 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.706 -176.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt -80.41 146.95 31.21 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.773 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 m -71.76 160.93 31.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.414 -175.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 17.6 tp60 -106.41 68.43 0.76 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.73 -177.091 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.64 45.28 54.03 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.736 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.54 -30.36 9.96 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.69 178.382 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 94.4 p -114.67 -161.98 0.8 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.431 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . 0.866 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 30.2 t -144.93 28.49 1.25 Allowed 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.692 0.758 . . . . 0.0 109.175 172.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.9 -61.65 2.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.112 -177.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.21 -20.35 63.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . 0.866 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 67.2 t -77.58 -58.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.741 0.305 . . . . 0.0 110.212 179.182 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 73.7 m -59.73 -30.33 68.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.354 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -56.51 -35.11 67.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.853 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -91.41 -35.93 14.09 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.75 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.6 t -71.48 -61.64 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.609 -177.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . 0.526 HG13 ' H ' ' 1' ' 23' ' ' VAL . 39.5 pt -102.33 -30.02 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.786 -0.366 . . . . 0.0 111.709 -176.025 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.04 -25.57 6.36 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.056 178.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . 0.526 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.2 t -95.96 148.29 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.011 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.52 28.31 3.83 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.073 0.464 . . . . 0.0 111.367 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . 0.524 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -105.95 120.08 40.83 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.728 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -167.39 139.6 5.81 Favored Glycine 0 N--CA 1.441 -1.026 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.801 -178.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 60.8 mtpt -118.31 173.02 7.05 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.659 0.266 . . . . 0.0 110.296 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 38.9 t -115.9 127.1 54.74 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.037 -177.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 57.0 mt -124.8 104.44 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.192 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 58.77 34.33 23.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.14 178.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.08 12.83 72.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.36 179.162 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 12.9 mmt85 -120.66 153.76 36.44 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.8 0.333 . . . . 0.0 110.175 176.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 5.8 t -94.41 142.01 27.91 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.184 0.516 . . . . 0.0 111.576 -172.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.16 115.64 27.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.895 172.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . 0.407 ' HB2' ' HB ' ' 1' ' 2' ' ' ILE . 75.6 m -85.09 142.0 29.85 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.065 -177.28 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 46.3 m-85 -122.16 94.14 48.16 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.01 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo . . . . . 0 C--O 1.25 1.105 0 C-N-CA 123.185 2.59 . . . . 0.0 111.589 175.805 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 120.633 0.254 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 33.8 mt -113.4 93.62 2.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.728 -178.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . 0.444 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 9.2 mp0 -76.81 104.71 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 174.538 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 57.8 p -94.51 165.74 12.39 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.473 -0.331 . . . . 0.0 110.537 -178.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -91.63 28.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.112 0.482 . . . . 0.0 111.204 -178.397 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 31.5 mtmm -93.68 149.62 21.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.275 176.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -84.96 143.11 29.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.718 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . 0.693 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 3.6 m -57.56 152.26 15.27 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.751 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 58.7 tp60 -118.05 69.59 0.79 Allowed 'General case' 0 N--CA 1.451 -0.411 0 CA-C-O 121.224 0.535 . . . . 0.0 110.118 -177.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.83 59.97 1.64 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 177.275 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.51 -34.98 2.86 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.073 176.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 50.1 m -133.22 -179.77 5.71 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.877 0.37 . . . . 0.0 110.506 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . 0.693 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.0 m -132.14 30.2 4.26 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.937 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -60.66 -48.79 80.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.272 -177.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . 0.497 ' HA ' ' HE ' ' 1' ' 18' ' ' ARG . 25.3 m -75.04 -25.92 59.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.957 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . 0.554 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.0 t -62.07 -56.58 16.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.104 0.478 . . . . 0.0 109.798 175.097 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 66.7 m -66.88 -24.64 66.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.144 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . 0.497 ' HE ' ' HA ' ' 1' ' 15' ' ' SER . 10.1 ttm-85 -62.92 -30.73 71.77 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-O 121.225 0.536 . . . . 0.0 109.77 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -87.95 -38.79 15.26 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.778 178.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . 0.554 HG23 ' O ' ' 1' ' 16' ' ' VAL . 43.8 t -68.45 -66.02 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.257 -177.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 31.2 pt -109.65 -10.46 11.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.83 0.348 . . . . 0.0 111.735 -175.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 109.48 -32.87 6.46 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.345 -0.931 . . . . 0.0 113.381 174.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . 0.473 HG21 ' O ' ' 1' ' 36' ' ' TYR . 14.6 m -81.76 144.79 9.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.997 0.427 . . . . 0.0 110.774 -177.081 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.54 44.23 1.17 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.483 0.659 . . . . 0.0 110.329 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . 0.432 ' HB1' ' HB2' ' 1' ' 36' ' ' TYR . . . -117.68 106.19 12.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.817 177.183 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . 0.664 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -163.36 126.2 1.5 Allowed Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.037 -176.383 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -112.16 164.98 12.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.81 0.338 . . . . 0.0 111.103 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.7 t -102.89 93.91 5.3 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.094 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 60.0 mt -104.17 105.74 19.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.309 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 60.08 37.48 21.01 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 123.293 0.371 . . . . 0.0 111.595 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.06 26.49 70.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.883 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -126.05 156.32 40.15 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 62.9 m -105.87 110.03 22.18 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.001 0.429 . . . . 0.0 111.132 -177.364 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . 0.664 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -98.88 119.45 46.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.275 176.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.0 m -95.85 138.51 33.39 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.619 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . 0.473 ' O ' HG21 ' 1' ' 23' ' ' VAL . 37.7 m-85 -114.0 100.82 53.21 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.857 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo . . . . . 0 C--O 1.251 1.175 0 C-N-CA 122.832 2.355 . . . . 0.0 112.414 178.496 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.758 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 44.7 mm -123.56 101.84 10.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.683 0.278 . . . . 0.0 111.196 -177.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -75.5 99.24 4.16 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 172.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 82.4 p -90.08 154.91 19.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.638 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 5' ' ' ASN . . . . . 0.472 ' HA ' ' HD2' ' 1' ' 32' ' ' ARG . 86.2 m-20 -81.14 31.22 0.32 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.986 0.422 . . . . 0.0 111.414 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -93.8 139.41 30.89 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.831 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 7' ' ' LYS . . . . . 0.558 ' HD3' ' H ' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -74.1 146.64 43.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.095 177.508 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' 1' 1 ' 8' ' ' CYS . . . . . 0.742 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.2 m -61.98 153.07 30.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.137 -176.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -98.25 76.72 2.35 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.297 0.57 . . . . 0.0 109.483 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -70.65 3.1 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.231 -178.135 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.63 -23.89 0.5 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.981 -179.216 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 47.5 m -141.2 -177.94 5.35 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 122.634 -0.333 . . . . 0.0 110.158 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 13' ' ' CYS . . . . . 0.742 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 72.7 m -131.43 25.04 4.81 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.093 0.473 . . . . 0.0 110.803 -178.52 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.281 -178.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 20.4 m -70.78 -31.24 67.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.707 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 16' ' ' VAL . . . . . 0.475 ' O ' HG23 ' 1' ' 20' ' ' VAL . 77.5 t -62.4 -53.4 47.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.05 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 79.1 m -65.82 -29.98 70.54 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.918 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.4 ttt180 -65.5 -31.37 72.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.147 0.499 . . . . 0.0 110.268 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -81.99 -40.16 22.57 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.719 177.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 20' ' ' VAL . . . . . 0.475 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.4 t -70.77 -70.28 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.535 -178.596 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 28.8 pt -100.21 -29.23 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -174.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.1 -37.03 2.37 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.072 -1.061 . . . . 0.0 113.378 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.4 m -74.78 145.91 10.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 117.002 0.401 . . . . 0.0 110.673 -178.071 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -95.64 40.65 1.11 Allowed 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.396 0.617 . . . . 0.0 110.484 -178.261 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -119.18 106.77 12.69 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.518 175.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 26' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -157.43 120.52 0.99 Allowed Glycine 0 N--CA 1.444 -0.826 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.305 -177.588 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 57.0 mtpt -111.17 159.07 18.21 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 120.983 0.42 . . . . 0.0 111.14 -174.048 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 53.8 t -97.37 114.78 26.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.601 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 69.9 mt -123.09 103.13 12.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.429 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 55.12 36.41 26.92 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.801 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 83.59 22.3 56.38 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.347 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 32' ' ' ARG . . . . . 0.472 ' HD2' ' HA ' ' 1' ' 5' ' ' ASN . 36.6 mmt180 -124.28 156.21 37.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.699 0.285 . . . . 0.0 110.408 177.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 88.8 m -108.12 107.45 18.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.227 -177.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 34' ' ' VAL . . . . . 0.465 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 3.6 p -94.38 111.82 25.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.43 0.633 . . . . 0.0 110.233 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.11 139.58 30.43 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -118.43 90.02 37.83 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.001 -178.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo . . . . . 0 C--O 1.248 1.017 0 C-N-CA 122.641 2.227 . . . . 0.0 111.833 176.267 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 39.3 mm . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 121.176 0.513 . . . . 0.0 110.525 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . 0.421 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 29.7 mt-10 -81.75 92.96 6.72 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.756 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 75.5 p -86.4 145.62 26.79 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.11 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -83.64 52.47 2.26 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.737 0.779 . . . . 0.0 110.252 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . 0.564 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 67.4 mttm -105.88 157.62 17.35 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.32 177.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . 0.536 ' HD2' ' O ' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -82.15 144.5 30.7 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.716 0.293 . . . . 0.0 110.262 177.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . 0.641 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.7 m -67.67 150.09 49.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.71 -177.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -96.47 72.26 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 94.97 -77.96 0.88 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.567 -177.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.3 -15.27 0.9 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 16.2 m -144.36 -177.61 5.56 Favored 'General case' 0 C--N 1.324 -0.519 0 O-C-N 122.591 -0.358 . . . . 0.0 110.131 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . 0.641 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.9 m -134.78 27.26 3.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.636 -177.439 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.31 -47.22 83.15 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.425 -178.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 18.6 t -70.61 -30.71 67.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.131 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . 0.496 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.7 t -62.71 -54.07 38.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.223 175.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.71 -28.04 68.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.128 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -64.65 -27.04 68.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.138 176.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 1.5 tmtp? -87.9 -46.28 9.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.881 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . 0.496 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.9 t -61.86 -60.36 2.83 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.898 -176.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 19.1 pt -109.06 -34.82 2.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.616 -0.265 . . . . 0.0 111.683 -176.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 135.72 -39.87 1.61 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.052 -1.071 . . . . 0.0 113.145 177.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 29.5 m -79.13 147.32 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.962 0.41 . . . . 0.0 110.865 -177.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.71 42.32 1.1 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.448 0.642 . . . . 0.0 110.318 -179.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' 1' ' 36' ' ' TYR . . . -116.07 108.22 15.93 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.896 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -171.86 131.19 2.1 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.947 -177.448 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -125.93 166.17 17.41 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.846 0.355 . . . . 0.0 111.147 -173.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.44 91.93 6.05 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.964 -175.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.05 118.88 53.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.94 177.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 57.55 27.77 14.6 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.766 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.12 11.77 84.02 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.337 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . 0.564 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 10.5 mpt_? -116.19 165.8 12.75 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.061 0.458 . . . . 0.0 110.612 178.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 92.0 m -104.22 106.38 16.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.172 -176.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . 0.476 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 2.7 p -97.35 113.15 31.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.38 0.61 . . . . 0.0 110.159 174.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.9 m -85.85 145.6 27.12 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.04 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . 0.425 ' HB2' ' HB1' ' 1' ' 25' ' ' ALA . 27.5 m-85 -119.77 79.66 23.84 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.086 -177.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo . . . . . 0 C--O 1.249 1.069 0 C-N-CA 122.715 2.276 . . . . 0.0 112.521 177.918 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 52.5 mt . . . . . 0 N--CA 1.456 -0.13 0 CA-C-O 120.784 0.326 . . . . 0.0 111.3 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . 0.422 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 38.0 mt-10 -77.82 114.97 17.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.023 172.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 58.7 p -100.84 154.02 19.0 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.847 -178.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -81.73 48.77 1.24 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.098 0.475 . . . . 0.0 110.751 -178.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . 0.419 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 93.1 mttt -119.57 166.49 13.09 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . 0.527 ' O ' ' HD3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -94.46 144.73 25.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.7 178.705 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 48.0 m -69.86 163.35 26.09 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.287 -176.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -107.18 36.15 2.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.336 0.589 . . . . 0.0 110.546 -175.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.81 82.02 1.53 Allowed Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.224 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.8 -40.85 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.595 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 41.1 t -142.49 -176.04 4.69 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -142.3 28.72 1.66 Allowed 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.513 0.673 . . . . 0.0 109.377 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.37 -36.06 79.18 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.151 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 7.9 p -63.76 -41.68 97.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.161 0.505 . . . . 0.0 110.645 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . 0.461 ' O ' HG23 ' 1' ' 20' ' ' VAL . 54.0 t -66.72 -47.07 84.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.574 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -60.04 -30.9 69.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.326 178.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 79.1 ttt180 -67.43 -21.16 65.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.04 0.447 . . . . 0.0 110.5 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -95.0 -33.61 12.66 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.088 0.471 . . . . 0.0 110.223 177.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' 1' ' 16' ' ' VAL . 63.3 t -72.39 -67.97 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.284 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . 0.508 HG13 ' H ' ' 1' ' 23' ' ' VAL . 43.8 pt -97.86 -12.96 8.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.754 0.311 . . . . 0.0 111.501 -176.088 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.56 4.95 63.59 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.963 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . 0.508 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -121.41 146.41 26.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.45 38.9 1.23 Allowed 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.115 0.483 . . . . 0.0 110.956 -175.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -109.98 113.34 25.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.621 176.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -168.51 162.8 36.59 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.21 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 55.6 mtmt -141.06 175.29 9.74 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 18.0 t -105.9 111.42 24.06 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.05 177.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 58.9 mt -118.29 112.13 36.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.787 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 59.39 29.23 18.77 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.425 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.74 85.6 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.317 -178.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 33.4 mmt180 -114.27 162.3 16.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.036 0.446 . . . . 0.0 110.801 179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 63.6 m -98.71 109.76 22.46 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.058 -173.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' 1' ' 3' ' ' GLU . 7.3 p -97.28 122.26 48.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.031 0.443 . . . . 0.0 110.087 176.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 68.3 m -101.07 140.0 35.98 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.614 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -116.04 98.51 51.33 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.788 -179.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 122.65 2.233 . . . . 0.0 112.203 177.806 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 46.7 mt . . . . . 0 N--CA 1.453 -0.282 0 CA-C-O 120.815 0.341 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . 0.492 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 47.4 mt-10 -74.38 100.66 3.85 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.167 0.508 . . . . 0.0 110.273 174.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 73.4 p -90.05 168.07 12.27 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.091 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -87.89 13.94 9.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.377 0.608 . . . . 0.0 110.009 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -73.58 148.45 42.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.775 176.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . 0.492 ' N ' ' HD2' ' 1' ' 7' ' ' LYS . 12.7 mptt -95.19 145.85 24.74 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.585 -178.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . 0.669 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 12.8 m -59.42 153.56 18.95 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.735 -175.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -135.05 108.78 8.01 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.903 -177.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 76.88 16.95 80.33 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.906 -178.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.8 1.01 63.76 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.557 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 96.6 p -150.96 -179.42 7.28 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.757 0.313 . . . . 0.0 110.747 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . 0.669 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 92.5 m -133.74 25.15 4.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.009 0.433 . . . . 0.0 110.908 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.27 75.86 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.628 179.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -73.4 -29.54 62.67 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.414 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 88.3 t -63.69 -56.28 17.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.2 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.478 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 95.8 m -66.62 -22.35 66.12 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.367 -178.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -63.54 -24.33 67.77 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.07 0.462 . . . . 0.0 110.228 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -96.17 -35.18 11.4 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.375 176.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 68.4 t -70.44 -64.32 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.48 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . 0.44 HG13 ' H ' ' 1' ' 23' ' ' VAL . 40.1 pt -97.9 -30.2 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.756 0.312 . . . . 0.0 111.158 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.46 -32.45 4.3 Favored Glycine 0 CA--C 1.508 -0.372 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.535 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . 0.44 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.0 t -89.69 147.65 5.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.815 0.341 . . . . 0.0 110.154 -178.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.2 48.42 1.5 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.227 0.536 . . . . 0.0 111.225 -175.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -124.62 112.47 16.84 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.054 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . 0.531 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.09 125.14 1.3 Allowed Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.041 -177.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 56.9 mtpt -107.66 165.71 11.22 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.945 0.402 . . . . 0.0 110.719 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.4 t -100.75 100.17 10.81 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.721 -177.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 67.5 mt -109.18 107.39 22.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.556 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 57.01 32.06 21.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.401 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . 0.404 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 87.6 -1.15 85.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.632 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 11.2 mpt_? -105.56 157.47 17.37 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.952 0.406 . . . . 0.0 110.62 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 90.3 m -100.47 110.34 22.52 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.591 -175.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . 0.531 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -92.96 107.85 19.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.698 0.761 . . . . 0.0 110.017 175.317 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 66.4 m -85.56 139.22 31.63 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.564 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -117.84 101.76 51.78 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.343 178.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo . . . . . 0 C--O 1.248 1.003 0 C-N-CA 122.641 2.227 . . . . 0.0 112.437 179.835 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.0 mt . . . . . 0 N--CA 1.456 -0.15 0 CA-C-O 120.566 0.222 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 33.5 mt-10 -74.04 90.39 1.99 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.099 0.476 . . . . 0.0 110.293 173.169 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 69.2 p -75.75 156.15 34.89 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.265 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -83.3 37.35 0.56 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.761 0.791 . . . . 0.0 110.314 -178.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -111.42 152.98 26.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.509 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . 0.413 ' HA ' ' O ' ' 1' ' 31' ' ' GLY . 0.8 OUTLIER -93.64 138.46 31.85 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.795 0.331 . . . . 0.0 110.675 -179.206 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . 0.581 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 1.5 p -57.45 148.39 23.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.506 -177.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -91.02 66.6 5.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.408 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 78.8 45.92 8.92 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.463 178.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 118.43 -69.04 0.33 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.525 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 15.2 m -109.15 176.08 5.22 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.938 0.399 . . . . 0.0 110.689 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . 0.581 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 83.1 m -124.02 30.51 6.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.621 -178.322 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 -50.03 75.43 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.647 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.9 m -67.52 -39.15 85.08 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.053 179.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . 0.45 ' O ' HG23 ' 1' ' 20' ' ' VAL . 59.1 t -61.8 -55.91 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.783 -178.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 74.6 m -67.02 -26.69 66.9 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.07 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -64.87 -30.44 71.44 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.108 0.48 . . . . 0.0 110.237 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -83.58 -32.83 25.59 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.504 178.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . 0.45 HG23 ' O ' ' 1' ' 16' ' ' VAL . 60.6 t -81.78 -64.59 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.807 -176.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . 0.511 HG13 ' H ' ' 1' ' 23' ' ' VAL . 45.4 pt -100.05 -9.71 8.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.63 -175.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.29 2.68 70.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.904 177.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . 0.511 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -116.73 143.48 26.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.15 39.64 1.08 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.474 0.655 . . . . 0.0 111.222 -175.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -115.33 109.69 18.29 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.625 175.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -165.32 129.77 2.03 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.047 -176.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -118.98 169.27 10.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' 1' ' 32' ' ' ARG . 11.7 t -106.25 116.72 32.42 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-O 120.969 0.414 . . . . 0.0 110.611 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 75.8 mt -116.42 105.29 18.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.015 177.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 86.3 m-20 55.63 39.24 30.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.318 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 85.67 4.04 85.63 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.898 178.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . 0.483 ' O ' ' HA ' ' 1' ' 28' ' ' CYS . 10.6 mpt_? -107.75 158.82 16.97 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.858 0.361 . . . . 0.0 110.731 178.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . 0.469 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 21.2 m -103.44 106.39 16.89 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.366 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . 0.449 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 6.0 p -88.65 104.65 14.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.706 0.765 . . . . 0.0 110.011 175.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 72.2 m -83.11 136.61 34.4 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -114.83 100.23 53.14 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.471 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 C--O 1.249 1.041 0 C-N-CA 123.03 2.487 . . . . 0.0 111.337 174.854 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.8 mt . . . . . 0 N--CA 1.455 -0.182 0 CA-C-O 120.561 0.219 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.15 115.06 13.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.96 0.41 . . . . 0.0 110.122 173.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 50.9 p -105.16 158.67 16.42 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.348 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -87.17 53.18 2.73 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.617 0.722 . . . . 0.0 109.738 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -128.07 157.96 39.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.159 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 32.4 mttp -86.69 147.77 25.73 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.872 -177.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -89.59 171.12 9.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.892 -179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 16.1 mp0 -95.44 26.99 3.56 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.913 179.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 88.27 91.11 1.09 Allowed Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.829 -177.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.29 -47.44 3.09 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.679 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 48.9 m -127.31 172.36 10.68 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.149 0.499 . . . . 0.0 111.464 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . 0.858 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 49.2 t -138.47 37.56 2.25 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.207 -179.086 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.39 -46.85 85.58 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.956 -175.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 13.1 p -71.84 -39.86 69.44 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -174.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . 0.858 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 76.4 t -63.83 -54.95 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.59 0.233 . . . . 0.0 110.519 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 94.0 m -58.34 -34.0 70.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.79 178.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 51.1 ttp180 -64.84 -29.57 70.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.931 0.396 . . . . 0.0 110.706 178.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -86.49 -40.0 15.71 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.222 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . 0.479 HG23 ' O ' ' 1' ' 16' ' ' VAL . 59.3 t -68.43 -68.13 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.45 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 32.2 pt -101.48 -32.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.813 -174.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 134.46 -41.87 1.41 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.019 -1.086 . . . . 0.0 113.56 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.9 m -78.35 148.03 6.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.989 0.394 . . . . 0.0 110.952 -176.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -96.32 33.3 1.8 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.399 0.619 . . . . 0.0 110.204 179.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -107.0 110.63 22.83 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.528 175.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -163.51 141.28 7.02 Favored Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.669 -176.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -122.36 175.87 6.19 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.823 0.344 . . . . 0.0 110.279 -177.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 19.2 t -115.91 109.5 17.69 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.834 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 74.3 mt -107.31 108.02 24.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.072 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 56.77 40.35 29.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.546 177.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.24 1.19 90.33 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.617 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . 0.479 ' HA ' ' HE ' ' 1' ' 32' ' ' ARG . 1.1 mmp_? -105.67 165.27 11.29 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.971 0.415 . . . . 0.0 110.424 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 15.1 t -101.88 129.53 48.15 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.545 -176.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 p -120.92 115.78 47.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.255 0.55 . . . . 0.0 110.286 175.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 80.3 m -88.48 141.1 28.81 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.107 -177.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -120.05 88.43 40.89 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.213 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo . . . . . 0 C--O 1.248 1.016 0 C-N-CA 122.788 2.325 . . . . 0.0 112.51 -178.562 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 55.2 mt . . . . . 0 N--CA 1.452 -0.371 0 CA-C-O 121.266 0.555 . . . . 0.0 110.782 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . 0.443 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 43.1 mt-10 -70.77 132.94 46.09 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.167 173.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 66.8 p -128.04 168.02 15.9 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.038 0.447 . . . . 0.0 110.373 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -85.98 -3.96 59.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.327 0.584 . . . . 0.0 110.391 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 27.7 mtpp -65.51 150.54 48.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.744 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -88.08 144.41 26.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.892 -174.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 5.0 m -68.5 168.57 12.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.114 -174.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 27.4 mm-40 -124.0 64.32 1.06 Allowed 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.784 -177.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.31 39.51 6.35 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.756 177.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.5 -6.05 74.4 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.248 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 87.9 p -133.76 -175.06 3.7 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . 0.873 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 25.6 t -143.73 29.26 1.39 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.362 0.601 . . . . 0.0 109.779 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.62 -47.24 86.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.383 -176.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.02 -38.17 79.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.595 -177.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . 0.873 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 54.2 t -69.9 -50.85 45.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.885 0.374 . . . . 0.0 110.593 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 83.9 m -60.77 -31.2 70.56 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.975 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . 0.423 ' O ' ' HA2' ' 1' ' 22' ' ' GLY . 49.5 ttp180 -64.46 -25.16 67.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.109 0.481 . . . . 0.0 110.161 178.548 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -85.49 -44.58 12.58 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.403 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.9 t -69.38 -66.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.925 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . 0.512 HG13 ' H ' ' 1' ' 23' ' ' VAL . 38.0 pt -94.28 -22.86 5.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.701 0.286 . . . . 0.0 111.5 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' 1' ' 18' ' ' ARG . . . 99.77 10.79 45.68 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.439 -0.886 . . . . 0.0 112.616 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . 0.512 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.9 t -126.13 146.71 31.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.97 38.85 1.07 Allowed 'General case' 0 C--N 1.314 -0.976 0 CA-C-O 121.516 0.674 . . . . 0.0 110.597 -176.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -111.24 108.54 18.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-N 115.267 -0.878 . . . . 0.0 109.536 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.3 140.02 6.1 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.03 -175.548 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . 0.438 ' HE2' ' CE1' ' 1' ' 36' ' ' TYR . 52.0 mtmt -123.61 177.5 5.65 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.837 0.351 . . . . 0.0 110.436 -177.152 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 22.2 t -113.96 115.69 28.05 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.597 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 79.4 mt -112.12 101.85 13.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.249 177.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 53.98 43.07 31.34 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.62 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.4 9.62 85.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.851 178.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 50.1 mmt-85 -118.76 150.71 39.34 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.0 110.179 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 10.3 t -85.31 144.31 28.15 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.067 -176.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . 0.461 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 6.8 p -135.19 116.77 20.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.287 0.565 . . . . 0.0 110.168 173.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . 0.404 ' HB3' HD13 ' 1' ' 21' ' ' ILE . 99.8 m -95.14 138.3 33.03 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.624 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . 0.438 ' CE1' ' HE2' ' 1' ' 27' ' ' LYS . 19.4 m-85 -116.2 98.34 51.17 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.247 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo . . . . . 0 C--O 1.25 1.122 0 C-N-CA 122.933 2.422 . . . . 0.0 111.938 177.654 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 51.4 mt . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.766 0.317 . . . . 0.0 111.278 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -71.08 93.46 1.03 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.886 0.375 . . . . 0.0 110.644 175.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 46.7 p -81.68 149.77 28.35 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.232 177.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -82.29 53.95 2.42 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.368 0.604 . . . . 0.0 110.438 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -109.69 146.07 35.47 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.482 178.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 45.8 mtpt -79.49 133.45 36.51 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 172.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . 0.642 ' HA ' ' SG ' ' 1' ' 33' ' ' CYS . 3.8 m -56.06 139.68 46.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.156 0.503 . . . . 0.0 110.69 -177.173 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 28.9 tt0 -89.23 56.58 3.71 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.693 -174.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 103.38 -71.53 0.28 Allowed Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.735 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -132.78 -30.2 0.5 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.25 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 5.4 m -132.75 -178.75 5.08 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . 0.494 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 1.1 m -134.09 35.59 3.28 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.271 174.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.14 -48.74 80.21 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.014 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.6 m -68.9 -32.84 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.198 0.523 . . . . 0.0 110.29 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 55.4 t -62.96 -53.76 42.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.441 177.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 82.5 m -66.38 -24.45 66.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.43 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -63.23 -28.46 70.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.09 0.472 . . . . 0.0 110.064 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -89.41 -36.59 15.38 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.28 178.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.1 t -73.63 -61.37 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.819 -177.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 44.4 pt -106.98 -5.96 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -175.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.72 11.12 71.54 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.542 -0.837 . . . . 0.0 113.176 176.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -122.15 143.89 33.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.74 46.07 1.22 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.516 0.674 . . . . 0.0 110.886 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . 0.483 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -129.23 114.14 15.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.739 175.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -157.65 120.21 0.96 Allowed Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.523 -177.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -108.22 157.2 18.54 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 -174.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 44.5 t -101.14 122.95 44.51 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.827 -177.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 54.6 mt -126.89 103.22 10.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.298 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 52.81 44.47 30.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.593 -0.731 . . . . 0.0 112.153 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.55 -19.93 51.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.24 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -100.37 163.79 12.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -178.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . 0.642 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 76.4 m -118.94 124.93 48.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.195 0.522 . . . . 0.0 111.765 -175.27 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . 0.401 HG13 ' HE2' ' 1' ' 36' ' ' TYR . 2.7 p -102.96 121.3 53.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.285 177.517 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 73.3 m -90.02 138.97 31.07 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.594 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . 0.483 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 70.1 m-85 -118.16 109.77 40.4 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.115 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo . . . . . 0 C--O 1.249 1.043 0 C-N-CA 122.837 2.358 . . . . 0.0 112.563 178.815 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . 0.407 ' HB ' ' HB2' ' 1' ' 35' ' ' CYS . 67.5 mt . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.976 0.417 . . . . 0.0 111.376 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -70.78 120.09 15.88 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.805 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 76.2 p -113.47 161.98 16.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.358 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -87.23 13.85 8.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 110.88 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -85.29 156.1 21.07 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.706 -176.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt -80.41 146.95 31.21 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.773 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 m -71.76 160.93 31.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.414 -175.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 17.6 tp60 -106.41 68.43 0.76 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.73 -177.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.64 45.28 54.03 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.736 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.54 -30.36 9.96 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.69 178.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 94.4 p -114.67 -161.98 0.8 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . 0.866 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 30.2 t -144.93 28.49 1.25 Allowed 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.692 0.758 . . . . 0.0 109.175 172.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.9 -61.65 2.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.112 -177.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.21 -20.35 63.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . 0.866 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 67.2 t -77.58 -58.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.741 0.305 . . . . 0.0 110.212 179.182 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 73.7 m -59.73 -30.33 68.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.354 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -56.51 -35.11 67.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.853 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -91.41 -35.93 14.09 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.75 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.6 t -71.48 -61.64 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.609 -177.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . 0.526 HG13 ' H ' ' 1' ' 23' ' ' VAL . 39.5 pt -102.33 -30.02 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.786 -0.366 . . . . 0.0 111.709 -176.025 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.04 -25.57 6.36 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.056 178.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . 0.526 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.2 t -95.96 148.29 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.52 28.31 3.83 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.073 0.464 . . . . 0.0 111.367 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . 0.524 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -105.95 120.08 40.83 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.728 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -167.39 139.6 5.81 Favored Glycine 0 N--CA 1.441 -1.026 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.801 -178.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 60.8 mtpt -118.31 173.02 7.05 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.659 0.266 . . . . 0.0 110.296 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 38.9 t -115.9 127.1 54.74 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.037 -177.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 57.0 mt -124.8 104.44 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.192 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 58.77 34.33 23.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.14 178.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.08 12.83 72.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.36 179.162 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 12.9 mmt85 -120.66 153.76 36.44 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.8 0.333 . . . . 0.0 110.175 176.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 5.8 t -94.41 142.01 27.91 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.184 0.516 . . . . 0.0 111.576 -172.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.16 115.64 27.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.895 172.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . 0.407 ' HB2' ' HB ' ' 1' ' 2' ' ' ILE . 75.6 m -85.09 142.0 29.85 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.065 -177.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 46.3 m-85 -122.16 94.14 48.16 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.01 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo . . . . . 0 C--O 1.25 1.105 0 C-N-CA 123.185 2.59 . . . . 0.0 111.589 175.805 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 33.8 mt . . . . . 0 N--CA 1.453 -0.309 0 CA-C-O 120.652 0.263 . . . . 0.0 110.728 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . 0.444 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 9.2 mp0 -76.81 104.71 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 174.538 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 57.8 p -94.51 165.74 12.39 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.473 -0.331 . . . . 0.0 110.537 -178.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -91.63 28.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.112 0.482 . . . . 0.0 111.204 -178.397 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 31.5 mtmm -93.68 149.62 21.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.275 176.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -84.96 143.11 29.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.718 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . 0.693 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 3.6 m -57.56 152.26 15.27 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.751 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 8.6 tp-100 -118.05 69.59 0.79 Allowed 'General case' 0 N--CA 1.451 -0.411 0 CA-C-O 121.224 0.535 . . . . 0.0 110.118 -177.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.83 59.97 1.64 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 177.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.51 -34.98 2.86 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.073 176.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 50.1 m -133.22 -179.77 5.71 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.877 0.37 . . . . 0.0 110.506 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . 0.693 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.0 m -132.14 30.2 4.26 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.937 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -60.66 -48.79 80.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.272 -177.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . 0.497 ' HA ' ' HE ' ' 1' ' 18' ' ' ARG . 25.3 m -75.04 -25.92 59.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.957 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . 0.554 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.0 t -62.07 -56.58 16.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.104 0.478 . . . . 0.0 109.798 175.097 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 66.7 m -66.88 -24.64 66.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.144 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . 0.497 ' HE ' ' HA ' ' 1' ' 15' ' ' SER . 10.1 ttm-85 -62.92 -30.73 71.77 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-O 121.225 0.536 . . . . 0.0 109.77 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -87.95 -38.79 15.26 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.778 178.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . 0.554 HG23 ' O ' ' 1' ' 16' ' ' VAL . 43.8 t -68.45 -66.02 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.257 -177.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 31.2 pt -109.65 -10.46 11.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.83 0.348 . . . . 0.0 111.735 -175.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 109.48 -32.87 6.46 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.345 -0.931 . . . . 0.0 113.381 174.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . 0.473 HG21 ' O ' ' 1' ' 36' ' ' TYR . 14.6 m -81.76 144.79 9.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.997 0.427 . . . . 0.0 110.774 -177.081 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.54 44.23 1.17 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.483 0.659 . . . . 0.0 110.329 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . 0.432 ' HB1' ' HB2' ' 1' ' 36' ' ' TYR . . . -117.68 106.19 12.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.817 177.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . 0.664 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -163.36 126.2 1.5 Allowed Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.037 -176.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -112.16 164.98 12.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.81 0.338 . . . . 0.0 111.103 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.7 t -102.89 93.91 5.3 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.094 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 60.0 mt -104.17 105.74 19.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.309 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.08 37.48 21.01 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 123.293 0.371 . . . . 0.0 111.595 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.06 26.49 70.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.883 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -126.05 156.32 40.15 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 62.9 m -105.87 110.03 22.18 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.001 0.429 . . . . 0.0 111.132 -177.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . 0.664 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -98.88 119.45 46.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.275 176.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.0 m -95.85 138.51 33.39 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.619 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . 0.473 ' O ' HG21 ' 1' ' 23' ' ' VAL . 37.7 m-85 -114.0 100.82 53.21 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.857 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo . . . . . 0 C--O 1.251 1.175 0 C-N-CA 122.832 2.355 . . . . 0.0 112.414 178.496 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 44.7 mm . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.683 0.278 . . . . 0.0 111.196 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -75.5 99.24 4.16 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 172.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 82.4 p -90.08 154.91 19.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.638 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 5' ' ' ASN . . . . . 0.472 ' HA ' ' HD2' ' 1' ' 32' ' ' ARG . 86.2 m-20 -81.14 31.22 0.32 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.986 0.422 . . . . 0.0 111.414 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -93.8 139.41 30.89 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.831 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 7' ' ' LYS . . . . . 0.558 ' H ' ' HD3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -74.1 146.64 43.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.095 177.508 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' 1' 1 ' 8' ' ' CYS . . . . . 0.742 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.2 m -61.98 153.07 30.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.137 -176.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -98.25 76.72 2.35 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.297 0.57 . . . . 0.0 109.483 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -70.65 3.1 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.231 -178.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.63 -23.89 0.5 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.981 -179.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 47.5 m -141.2 -177.94 5.35 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 122.634 -0.333 . . . . 0.0 110.158 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 13' ' ' CYS . . . . . 0.742 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 72.7 m -131.43 25.04 4.81 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.093 0.473 . . . . 0.0 110.803 -178.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.281 -178.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 20.4 m -70.78 -31.24 67.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.707 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 16' ' ' VAL . . . . . 0.475 ' O ' HG23 ' 1' ' 20' ' ' VAL . 77.5 t -62.4 -53.4 47.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.05 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 79.1 m -65.82 -29.98 70.54 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.918 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.4 ttt180 -65.5 -31.37 72.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.147 0.499 . . . . 0.0 110.268 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -81.99 -40.16 22.57 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.719 177.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 20' ' ' VAL . . . . . 0.475 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.4 t -70.77 -70.28 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.535 -178.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 28.8 pt -100.21 -29.23 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -174.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.1 -37.03 2.37 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.072 -1.061 . . . . 0.0 113.378 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.4 m -74.78 145.91 10.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 117.002 0.401 . . . . 0.0 110.673 -178.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -95.64 40.65 1.11 Allowed 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.396 0.617 . . . . 0.0 110.484 -178.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -119.18 106.77 12.69 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.518 175.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 26' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -157.43 120.52 0.99 Allowed Glycine 0 N--CA 1.444 -0.826 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.305 -177.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 57.0 mtpt -111.17 159.07 18.21 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 120.983 0.42 . . . . 0.0 111.14 -174.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 53.8 t -97.37 114.78 26.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.601 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 69.9 mt -123.09 103.13 12.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.429 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 55.12 36.41 26.92 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.801 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 83.59 22.3 56.38 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.347 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 32' ' ' ARG . . . . . 0.472 ' HD2' ' HA ' ' 1' ' 5' ' ' ASN . 36.6 mmt180 -124.28 156.21 37.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.699 0.285 . . . . 0.0 110.408 177.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 88.8 m -108.12 107.45 18.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.227 -177.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 34' ' ' VAL . . . . . 0.465 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 3.6 p -94.38 111.82 25.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.43 0.633 . . . . 0.0 110.233 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.11 139.58 30.43 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -118.43 90.02 37.83 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.001 -178.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo . . . . . 0 C--O 1.248 1.017 0 C-N-CA 122.641 2.227 . . . . 0.0 111.833 176.267 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.815 0 CA-C-O 120.635 0.255 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 39.3 mm -95.62 91.6 2.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.176 0.513 . . . . 0.0 110.525 -177.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . 0.421 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 29.7 mt-10 -81.75 92.96 6.72 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.756 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 75.5 p -86.4 145.62 26.79 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.11 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -83.64 52.47 2.26 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.737 0.779 . . . . 0.0 110.252 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . 0.564 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 67.4 mttm -105.88 157.62 17.35 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.32 177.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . 0.536 ' HD2' ' O ' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -82.15 144.5 30.7 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.716 0.293 . . . . 0.0 110.262 177.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . 0.641 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.7 m -67.67 150.09 49.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.71 -177.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -96.47 72.26 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 94.97 -77.96 0.88 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.567 -177.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.3 -15.27 0.9 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 16.2 m -144.36 -177.61 5.56 Favored 'General case' 0 C--N 1.324 -0.519 0 O-C-N 122.591 -0.358 . . . . 0.0 110.131 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . 0.641 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.9 m -134.78 27.26 3.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.636 -177.439 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.31 -47.22 83.15 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.425 -178.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 18.6 t -70.61 -30.71 67.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.131 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . 0.496 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.7 t -62.71 -54.07 38.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.223 175.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.71 -28.04 68.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.128 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -64.65 -27.04 68.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.138 176.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 1.5 tmtp? -87.9 -46.28 9.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.881 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . 0.496 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.9 t -61.86 -60.36 2.83 Favored 'Isoleucine or valine' 0 C--O 1.234 0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.898 -176.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 19.1 pt -109.06 -34.82 2.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.616 -0.265 . . . . 0.0 111.683 -176.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 135.72 -39.87 1.61 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.052 -1.071 . . . . 0.0 113.145 177.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 29.5 m -79.13 147.32 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.962 0.41 . . . . 0.0 110.865 -177.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.71 42.32 1.1 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.448 0.642 . . . . 0.0 110.318 -179.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' 1' ' 36' ' ' TYR . . . -116.07 108.22 15.93 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.896 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -171.86 131.19 2.1 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.947 -177.448 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -125.93 166.17 17.41 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.846 0.355 . . . . 0.0 111.147 -173.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.44 91.93 6.05 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.964 -175.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 mp -105.05 118.88 53.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.94 177.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 57.55 27.77 14.6 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.766 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.12 11.77 84.02 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.337 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . 0.564 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 10.5 mpt_? -116.19 165.8 12.75 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.061 0.458 . . . . 0.0 110.612 178.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 92.0 m -104.22 106.38 16.86 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.172 -176.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . 0.476 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 2.7 p -97.35 113.15 31.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.38 0.61 . . . . 0.0 110.159 174.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.9 m -85.85 145.6 27.12 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.04 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . 0.425 ' HB2' ' HB1' ' 1' ' 25' ' ' ALA . 27.5 m-85 -119.77 79.66 23.84 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.086 -177.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo . . . . . 0 C--O 1.249 1.069 0 C-N-CA 122.715 2.276 . . . . 0.0 112.521 177.918 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 52.5 mt -107.13 95.35 3.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 120.784 0.326 . . . . 0.0 111.3 -175.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . 0.422 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 38.0 mt-10 -77.82 114.97 17.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.023 172.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 58.7 p -100.84 154.02 19.0 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.847 -178.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -81.73 48.77 1.24 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.098 0.475 . . . . 0.0 110.751 -178.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . 0.419 ' O ' ' HA ' ' 1' ' 32' ' ' ARG . 93.1 mttt -119.57 166.49 13.09 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . 0.527 ' O ' ' HD3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -94.46 144.73 25.32 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.7 178.705 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 48.0 m -69.86 163.35 26.09 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.287 -176.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -107.18 36.15 2.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.336 0.589 . . . . 0.0 110.546 -175.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.81 82.02 1.53 Allowed Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.224 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.8 -40.85 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.595 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 41.1 t -142.49 -176.04 4.69 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -142.3 28.72 1.66 Allowed 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 121.513 0.673 . . . . 0.0 109.377 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.37 -36.06 79.18 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.151 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 7.9 p -63.76 -41.68 97.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.161 0.505 . . . . 0.0 110.645 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . 0.461 ' O ' HG23 ' 1' ' 20' ' ' VAL . 54.0 t -66.72 -47.07 84.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.574 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 85.5 m -60.04 -30.9 69.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.326 178.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 79.1 ttt180 -67.43 -21.16 65.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.04 0.447 . . . . 0.0 110.5 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -95.0 -33.61 12.66 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.088 0.471 . . . . 0.0 110.223 177.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' 1' ' 16' ' ' VAL . 63.3 t -72.39 -67.97 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.284 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . 0.508 HG13 ' H ' ' 1' ' 23' ' ' VAL . 43.8 pt -97.86 -12.96 8.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.754 0.311 . . . . 0.0 111.501 -176.088 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.56 4.95 63.59 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.963 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . 0.508 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -121.41 146.41 26.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.45 38.9 1.23 Allowed 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.115 0.483 . . . . 0.0 110.956 -175.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -109.98 113.34 25.98 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.621 176.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -168.51 162.8 36.59 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.21 -177.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 55.6 mtmt -141.06 175.29 9.74 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 18.0 t -105.9 111.42 24.06 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.05 177.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 58.9 mt -118.29 112.13 36.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.787 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 59.39 29.23 18.77 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.425 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.68 8.74 85.6 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.317 -178.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' 1' ' 6' ' ' LYS . 33.4 mmt180 -114.27 162.3 16.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.036 0.446 . . . . 0.0 110.801 179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 63.6 m -98.71 109.76 22.46 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.058 -173.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' 1' ' 3' ' ' GLU . 7.3 p -97.28 122.26 48.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.031 0.443 . . . . 0.0 110.087 176.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 68.3 m -101.07 140.0 35.98 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.614 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -116.04 98.51 51.33 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.788 -179.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 122.65 2.233 . . . . 0.0 112.203 177.806 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 46.7 mt -124.7 91.84 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.815 0.341 . . . . 0.0 111.079 -179.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . 0.492 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 47.4 mt-10 -74.38 100.66 3.85 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.167 0.508 . . . . 0.0 110.273 174.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 73.4 p -90.05 168.07 12.27 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.091 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -87.89 13.94 9.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.377 0.608 . . . . 0.0 110.009 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -73.58 148.45 42.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.775 176.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . 0.492 ' N ' ' HD2' ' 1' ' 7' ' ' LYS . 12.7 mptt -95.19 145.85 24.74 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.585 -178.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . 0.669 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 12.8 m -59.42 153.56 18.95 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.735 -175.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -135.05 108.78 8.01 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.903 -177.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 76.88 16.95 80.33 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.906 -178.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.8 1.01 63.76 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.557 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 96.6 p -150.96 -179.42 7.28 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.757 0.313 . . . . 0.0 110.747 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . 0.669 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 92.5 m -133.74 25.15 4.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.009 0.433 . . . . 0.0 110.908 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.27 75.86 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.628 179.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -73.4 -29.54 62.67 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.414 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 88.3 t -63.69 -56.28 17.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.2 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.478 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 95.8 m -66.62 -22.35 66.12 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.367 -178.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -63.54 -24.33 67.77 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.07 0.462 . . . . 0.0 110.228 175.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -96.17 -35.18 11.4 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.375 176.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 68.4 t -70.44 -64.32 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.48 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . 0.44 HG13 ' H ' ' 1' ' 23' ' ' VAL . 40.1 pt -97.9 -30.2 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.756 0.312 . . . . 0.0 111.158 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.46 -32.45 4.3 Favored Glycine 0 CA--C 1.508 -0.372 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.535 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . 0.44 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.0 t -89.69 147.65 5.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.815 0.341 . . . . 0.0 110.154 -178.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.2 48.42 1.5 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.227 0.536 . . . . 0.0 111.225 -175.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -124.62 112.47 16.84 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.054 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . 0.531 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.09 125.14 1.3 Allowed Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.041 -177.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 56.9 mtpt -107.66 165.71 11.22 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.945 0.402 . . . . 0.0 110.719 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.4 t -100.75 100.17 10.81 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.721 -177.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 67.5 mt -109.18 107.39 22.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.556 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 57.01 32.06 21.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.401 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . 0.404 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 87.6 -1.15 85.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.632 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 11.2 mpt_? -105.56 157.47 17.37 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.952 0.406 . . . . 0.0 110.62 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 90.3 m -100.47 110.34 22.52 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.591 -175.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . 0.531 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -92.96 107.85 19.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.698 0.761 . . . . 0.0 110.017 175.317 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 66.4 m -85.56 139.22 31.63 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.564 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -117.84 101.76 51.78 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.343 178.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo . . . . . 0 C--O 1.248 1.003 0 C-N-CA 122.641 2.227 . . . . 0.0 112.437 179.835 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.863 0 N-CA-C 110.324 -0.25 . . . . 0.0 110.324 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.0 mt -124.23 98.87 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.215 -178.255 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 33.5 mt-10 -74.04 90.39 1.99 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.099 0.476 . . . . 0.0 110.293 173.169 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 69.2 p -75.75 156.15 34.89 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.265 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -83.3 37.35 0.56 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.761 0.791 . . . . 0.0 110.314 -178.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -111.42 152.98 26.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.509 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . 0.413 ' HA ' ' O ' ' 1' ' 31' ' ' GLY . 0.8 OUTLIER -93.64 138.46 31.85 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.795 0.331 . . . . 0.0 110.675 -179.206 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . 0.581 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 1.5 p -57.45 148.39 23.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.506 -177.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -91.02 66.6 5.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.408 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 78.8 45.92 8.92 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.463 178.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 118.43 -69.04 0.33 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.525 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 15.2 m -109.15 176.08 5.22 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.938 0.399 . . . . 0.0 110.689 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . 0.581 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 83.1 m -124.02 30.51 6.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.621 -178.322 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 -50.03 75.43 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.647 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.9 m -67.52 -39.15 85.08 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.053 179.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . 0.45 ' O ' HG23 ' 1' ' 20' ' ' VAL . 59.1 t -61.8 -55.91 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.783 -178.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 74.6 m -67.02 -26.69 66.9 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.07 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -64.87 -30.44 71.44 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.108 0.48 . . . . 0.0 110.237 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -83.58 -32.83 25.59 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.504 178.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . 0.45 HG23 ' O ' ' 1' ' 16' ' ' VAL . 60.6 t -81.78 -64.59 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.807 -176.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . 0.511 HG13 ' H ' ' 1' ' 23' ' ' VAL . 45.4 pt -100.05 -9.71 8.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.63 -175.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.29 2.68 70.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.904 177.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . 0.511 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.3 t -116.73 143.48 26.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.15 39.64 1.08 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.474 0.655 . . . . 0.0 111.222 -175.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -115.33 109.69 18.29 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.625 175.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -165.32 129.77 2.03 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.047 -176.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -118.98 169.27 10.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' 1' ' 32' ' ' ARG . 11.7 t -106.25 116.72 32.42 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-O 120.969 0.414 . . . . 0.0 110.611 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 75.8 mt -116.42 105.29 18.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.015 177.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 86.3 m-20 55.63 39.24 30.91 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.318 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' 1' ' 7' ' ' LYS . . . 85.67 4.04 85.63 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.898 178.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . 0.483 ' O ' ' HA ' ' 1' ' 28' ' ' CYS . 10.6 mpt_? -107.75 158.82 16.97 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.858 0.361 . . . . 0.0 110.731 178.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . 0.469 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 21.2 m -103.44 106.39 16.89 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.366 -177.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . 0.449 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 6.0 p -88.65 104.65 14.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.706 0.765 . . . . 0.0 110.011 175.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 72.2 m -83.11 136.61 34.4 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.493 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -114.83 100.23 53.14 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.471 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 C--O 1.249 1.041 0 C-N-CA 123.03 2.487 . . . . 0.0 111.337 174.854 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 120.725 0.297 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 47.8 mt -124.04 96.36 3.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.796 -179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.15 115.06 13.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.96 0.41 . . . . 0.0 110.122 173.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 50.9 p -105.16 158.67 16.42 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.348 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -87.17 53.18 2.73 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.617 0.722 . . . . 0.0 109.738 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -128.07 157.96 39.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.159 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 32.4 mttp -86.69 147.77 25.73 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.872 -177.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -89.59 171.12 9.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.892 -179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 16.1 mp0 -95.44 26.99 3.56 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.913 179.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 88.27 91.11 1.09 Allowed Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.829 -177.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.29 -47.44 3.09 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.679 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 48.9 m -127.31 172.36 10.68 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.149 0.499 . . . . 0.0 111.464 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . 0.858 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 49.2 t -138.47 37.56 2.25 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.207 -179.086 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.39 -46.85 85.58 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.956 -175.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 13.1 p -71.84 -39.86 69.44 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -174.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . 0.858 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 76.4 t -63.83 -54.95 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.59 0.233 . . . . 0.0 110.519 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 94.0 m -58.34 -34.0 70.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.79 178.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 51.1 ttp180 -64.84 -29.57 70.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.931 0.396 . . . . 0.0 110.706 178.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -86.49 -40.0 15.71 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.222 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . 0.479 HG23 ' O ' ' 1' ' 16' ' ' VAL . 59.3 t -68.43 -68.13 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.45 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 32.2 pt -101.48 -32.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.813 -174.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 134.46 -41.87 1.41 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.019 -1.086 . . . . 0.0 113.56 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.9 m -78.35 148.03 6.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.989 0.394 . . . . 0.0 110.952 -176.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -96.32 33.3 1.8 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.399 0.619 . . . . 0.0 110.204 179.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -107.0 110.63 22.83 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.528 175.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -163.51 141.28 7.02 Favored Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.669 -176.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -122.36 175.87 6.19 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.823 0.344 . . . . 0.0 110.279 -177.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 19.2 t -115.91 109.5 17.69 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.834 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 74.3 mt -107.31 108.02 24.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.072 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 56.77 40.35 29.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.546 177.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 82.24 1.19 90.33 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.617 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . 0.479 ' HA ' ' HE ' ' 1' ' 32' ' ' ARG . 1.1 mmp_? -105.67 165.27 11.29 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.971 0.415 . . . . 0.0 110.424 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 15.1 t -101.88 129.53 48.15 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.545 -176.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 p -120.92 115.78 47.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.255 0.55 . . . . 0.0 110.286 175.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 80.3 m -88.48 141.1 28.81 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.107 -177.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -120.05 88.43 40.89 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.213 178.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo . . . . . 0 C--O 1.248 1.016 0 C-N-CA 122.788 2.325 . . . . 0.0 112.51 -178.562 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . 0.527 ' HB2' ' CG2' ' 1' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.475 0.805 0 CA-C-O 120.64 0.257 . . . . 0.0 110.491 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 55.2 mt -89.01 90.7 3.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.266 0.555 . . . . 0.0 110.782 -177.019 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . 0.443 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 43.1 mt-10 -70.77 132.94 46.09 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.167 173.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 66.8 p -128.04 168.02 15.9 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.038 0.447 . . . . 0.0 110.373 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -85.98 -3.96 59.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.327 0.584 . . . . 0.0 110.391 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 27.7 mtpp -65.51 150.54 48.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.744 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -88.08 144.41 26.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.892 -174.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 5.0 m -68.5 168.57 12.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.114 -174.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 27.4 mm-40 -124.0 64.32 1.06 Allowed 'General case' 0 C--O 1.233 0.226 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.784 -177.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.31 39.51 6.35 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.756 177.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.5 -6.05 74.4 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.248 178.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 87.9 p -133.76 -175.06 3.7 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 -179.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . 0.873 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 25.6 t -143.73 29.26 1.39 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.362 0.601 . . . . 0.0 109.779 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.62 -47.24 86.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.383 -176.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.02 -38.17 79.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.595 -177.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . 0.873 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 54.2 t -69.9 -50.85 45.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.885 0.374 . . . . 0.0 110.593 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 83.9 m -60.77 -31.2 70.56 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.975 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . 0.423 ' O ' ' HA2' ' 1' ' 22' ' ' GLY . 49.5 ttp180 -64.46 -25.16 67.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.109 0.481 . . . . 0.0 110.161 178.548 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -85.49 -44.58 12.58 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.403 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.9 t -69.38 -66.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.925 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . 0.512 HG13 ' H ' ' 1' ' 23' ' ' VAL . 38.0 pt -94.28 -22.86 5.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.701 0.286 . . . . 0.0 111.5 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' 1' ' 18' ' ' ARG . . . 99.77 10.79 45.68 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.439 -0.886 . . . . 0.0 112.616 178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . 0.512 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.9 t -126.13 146.71 31.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.97 38.85 1.07 Allowed 'General case' 0 C--N 1.314 -0.976 0 CA-C-O 121.516 0.674 . . . . 0.0 110.597 -176.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -111.24 108.54 18.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-N 115.267 -0.878 . . . . 0.0 109.536 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -166.3 140.02 6.1 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.03 -175.548 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . 0.438 ' HE2' ' CE1' ' 1' ' 36' ' ' TYR . 52.0 mtmt -123.61 177.5 5.65 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.837 0.351 . . . . 0.0 110.436 -177.152 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 22.2 t -113.96 115.69 28.05 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.597 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 79.4 mt -112.12 101.85 13.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.249 177.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 53.98 43.07 31.34 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.62 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.4 9.62 85.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.851 178.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 50.1 mmt-85 -118.76 150.71 39.34 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.0 110.179 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 10.3 t -85.31 144.31 28.15 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.067 -176.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . 0.527 ' CG2' ' HB2' ' 1' ' 1' ' ' PCA . 6.8 p -135.19 116.77 20.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.287 0.565 . . . . 0.0 110.168 173.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . 0.404 ' HB3' HD13 ' 1' ' 21' ' ' ILE . 99.8 m -95.14 138.3 33.03 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.624 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . 0.438 ' CE1' ' HE2' ' 1' ' 27' ' ' LYS . 19.4 m-85 -116.2 98.34 51.17 Favored Pre-proline 0 C--N 1.324 -0.52 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.247 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo . . . . . 0 C--O 1.25 1.122 0 C-N-CA 122.933 2.422 . . . . 0.0 111.938 177.654 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.778 0 N-CA-C 110.386 -0.227 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 51.4 mt -96.46 95.28 4.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.766 0.317 . . . . 0.0 111.278 -175.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -71.08 93.46 1.03 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.886 0.375 . . . . 0.0 110.644 175.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 46.7 p -81.68 149.77 28.35 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.232 177.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -82.29 53.95 2.42 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.368 0.604 . . . . 0.0 110.438 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -109.69 146.07 35.47 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.482 178.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 45.8 mtpt -79.49 133.45 36.51 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 172.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . 0.642 ' HA ' ' SG ' ' 1' ' 33' ' ' CYS . 3.8 m -56.06 139.68 46.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.156 0.503 . . . . 0.0 110.69 -177.173 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 28.9 tt0 -89.23 56.58 3.71 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.693 -174.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 103.38 -71.53 0.28 Allowed Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.735 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -132.78 -30.2 0.5 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.25 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 5.4 m -132.75 -178.75 5.08 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . 0.494 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 1.1 m -134.09 35.59 3.28 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.271 174.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.14 -48.74 80.21 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.014 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 8.6 m -68.9 -32.84 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.198 0.523 . . . . 0.0 110.29 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . . . . . . . . . 55.4 t -62.96 -53.76 42.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.441 177.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 82.5 m -66.38 -24.45 66.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.43 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -63.23 -28.46 70.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.09 0.472 . . . . 0.0 110.064 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -89.41 -36.59 15.38 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.28 178.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.1 t -73.63 -61.37 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.819 -177.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 44.4 pt -106.98 -5.96 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -175.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.72 11.12 71.54 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.542 -0.837 . . . . 0.0 113.176 176.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -122.15 143.89 33.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 177.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.74 46.07 1.22 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.516 0.674 . . . . 0.0 110.886 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . 0.483 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -129.23 114.14 15.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.739 175.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -157.65 120.21 0.96 Allowed Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.523 -177.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -108.22 157.2 18.54 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 -174.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 44.5 t -101.14 122.95 44.51 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.827 -177.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 54.6 mt -126.89 103.22 10.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.298 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 52.81 44.47 30.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.593 -0.731 . . . . 0.0 112.153 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.55 -19.93 51.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.24 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -100.37 163.79 12.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -178.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . 0.642 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 76.4 m -118.94 124.93 48.25 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.195 0.522 . . . . 0.0 111.765 -175.27 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . 0.401 HG13 ' HE2' ' 1' ' 36' ' ' TYR . 2.7 p -102.96 121.3 53.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.285 177.517 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 73.3 m -90.02 138.97 31.07 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.594 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . 0.483 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 70.1 m-85 -118.16 109.77 40.4 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.115 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo . . . . . 0 C--O 1.249 1.043 0 C-N-CA 122.837 2.358 . . . . 0.0 112.563 178.815 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 CA-C-O 120.796 0.331 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . 0.407 ' HB ' ' HB2' ' 1' ' 35' ' ' CYS . 67.5 mt -108.68 94.83 3.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.976 0.417 . . . . 0.0 111.376 -175.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -70.78 120.09 15.88 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.805 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 76.2 p -113.47 161.98 16.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.358 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -87.23 13.85 8.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 110.88 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 48.8 mmtm -85.29 156.1 21.07 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.706 -176.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt -80.41 146.95 31.21 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.773 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 m -71.76 160.93 31.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.414 -175.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 17.6 tp60 -106.41 68.43 0.76 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.73 -177.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 70.64 45.28 54.03 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.736 178.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.54 -30.36 9.96 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.69 178.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 94.4 p -114.67 -161.98 0.8 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . 0.866 ' SG ' ' HB ' ' 1' ' 16' ' ' VAL . 30.2 t -144.93 28.49 1.25 Allowed 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.692 0.758 . . . . 0.0 109.175 172.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.9 -61.65 2.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.112 -177.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 19.3 m -69.21 -20.35 63.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . 0.866 ' HB ' ' SG ' ' 1' ' 13' ' ' CYS . 67.2 t -77.58 -58.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.741 0.305 . . . . 0.0 110.212 179.182 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 73.7 m -59.73 -30.33 68.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.354 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -56.51 -35.11 67.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.853 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -91.41 -35.93 14.09 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.75 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . . . . . . . . . 61.6 t -71.48 -61.64 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.609 -177.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . 0.526 HG13 ' H ' ' 1' ' 23' ' ' VAL . 39.5 pt -102.33 -30.02 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.786 -0.366 . . . . 0.0 111.709 -176.025 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.04 -25.57 6.36 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.056 178.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . 0.526 ' H ' HG13 ' 1' ' 21' ' ' ILE . 2.2 t -95.96 148.29 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -97.52 28.31 3.83 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.073 0.464 . . . . 0.0 111.367 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . 0.524 ' HB3' ' O ' ' 1' ' 36' ' ' TYR . . . -105.95 120.08 40.83 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.101 -0.499 . . . . 0.0 109.728 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . . . . . . . . . . . -167.39 139.6 5.81 Favored Glycine 0 N--CA 1.441 -1.026 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.801 -178.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 60.8 mtpt -118.31 173.02 7.05 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.659 0.266 . . . . 0.0 110.296 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 38.9 t -115.9 127.1 54.74 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.037 -177.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 57.0 mt -124.8 104.44 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.192 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 58.77 34.33 23.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.14 178.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.08 12.83 72.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.534 -0.841 . . . . 0.0 112.36 179.162 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 12.9 mmt85 -120.66 153.76 36.44 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.8 0.333 . . . . 0.0 110.175 176.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 5.8 t -94.41 142.01 27.91 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.184 0.516 . . . . 0.0 111.576 -172.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.16 115.64 27.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.895 172.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . 0.407 ' HB2' ' HB ' ' 1' ' 2' ' ' ILE . 75.6 m -85.09 142.0 29.85 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.065 -177.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' 1' ' 25' ' ' ALA . 46.3 m-85 -122.16 94.14 48.16 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.01 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo . . . . . 0 C--O 1.25 1.105 0 C-N-CA 123.185 2.59 . . . . 0.0 111.589 175.805 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 120.633 0.254 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 33.8 mt -113.4 93.62 2.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.728 -178.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . 0.444 ' HA ' ' HA ' ' 1' ' 34' ' ' VAL . 9.2 mp0 -76.81 104.71 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 174.538 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 57.8 p -94.51 165.74 12.39 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.473 -0.331 . . . . 0.0 110.537 -178.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -91.63 28.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.112 0.482 . . . . 0.0 111.204 -178.397 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 31.5 mtmm -93.68 149.62 21.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.275 176.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -84.96 143.11 29.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.718 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . 0.693 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 3.6 m -57.56 152.26 15.27 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.751 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 8.6 tp-100 -118.05 69.59 0.79 Allowed 'General case' 0 N--CA 1.451 -0.411 0 CA-C-O 121.224 0.535 . . . . 0.0 110.118 -177.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.83 59.97 1.64 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 177.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . 83.51 -34.98 2.86 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.016 -0.612 . . . . 0.0 113.073 176.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 50.1 m -133.22 -179.77 5.71 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.877 0.37 . . . . 0.0 110.506 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . 0.693 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 74.0 m -132.14 30.2 4.26 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.937 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -60.66 -48.79 80.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.272 -177.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . 0.497 ' HA ' ' HE ' ' 1' ' 18' ' ' ARG . 25.3 m -75.04 -25.92 59.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.957 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . 0.554 ' O ' HG23 ' 1' ' 20' ' ' VAL . 95.0 t -62.07 -56.58 16.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.104 0.478 . . . . 0.0 109.798 175.097 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 66.7 m -66.88 -24.64 66.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.144 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . 0.497 ' HE ' ' HA ' ' 1' ' 15' ' ' SER . 10.1 ttm-85 -62.92 -30.73 71.77 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-O 121.225 0.536 . . . . 0.0 109.77 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -87.95 -38.79 15.26 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.778 178.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . 0.554 HG23 ' O ' ' 1' ' 16' ' ' VAL . 43.8 t -68.45 -66.02 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.257 -177.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 31.2 pt -109.65 -10.46 11.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.83 0.348 . . . . 0.0 111.735 -175.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 109.48 -32.87 6.46 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.345 -0.931 . . . . 0.0 113.381 174.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . 0.473 HG21 ' O ' ' 1' ' 36' ' ' TYR . 14.6 m -81.76 144.79 9.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.997 0.427 . . . . 0.0 110.774 -177.081 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -91.54 44.23 1.17 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.483 0.659 . . . . 0.0 110.329 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . 0.432 ' HB1' ' HB2' ' 1' ' 36' ' ' TYR . . . -117.68 106.19 12.82 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.817 177.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . 0.664 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -163.36 126.2 1.5 Allowed Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.037 -176.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -112.16 164.98 12.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.81 0.338 . . . . 0.0 111.103 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 49.7 t -102.89 93.91 5.3 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.094 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 60.0 mt -104.17 105.74 19.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.309 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.08 37.48 21.01 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 123.293 0.371 . . . . 0.0 111.595 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.06 26.49 70.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.883 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -126.05 156.32 40.15 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 62.9 m -105.87 110.03 22.18 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.001 0.429 . . . . 0.0 111.132 -177.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . 0.664 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 7.6 p -98.88 119.45 46.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.275 176.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 74.0 m -95.85 138.51 33.39 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.619 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . 0.473 ' O ' HG21 ' 1' ' 23' ' ' VAL . 37.7 m-85 -114.0 100.82 53.21 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.857 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo . . . . . 0 C--O 1.251 1.175 0 C-N-CA 122.832 2.355 . . . . 0.0 112.414 178.496 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' 1' 1 ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.758 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' 1' 1 ' 2' ' ' ILE . . . . . . . . . . . . . 44.7 mm -123.56 101.84 10.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.683 0.278 . . . . 0.0 111.196 -177.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 3' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -75.5 99.24 4.16 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 172.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 4' ' ' THR . . . . . . . . . . . . . 82.4 p -90.08 154.91 19.44 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.638 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 5' ' ' ASN . . . . . 0.472 ' HA ' ' HD2' ' 1' ' 32' ' ' ARG . 86.2 m-20 -81.14 31.22 0.32 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.986 0.422 . . . . 0.0 111.414 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' 1' 1 ' 6' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -93.8 139.41 30.89 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.831 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 7' ' ' LYS . . . . . 0.558 ' H ' ' HD3' ' 1' ' 7' ' ' LYS . 0.0 OUTLIER -74.1 146.64 43.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.095 177.508 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' 1' 1 ' 8' ' ' CYS . . . . . 0.742 ' HA ' ' SG ' ' 1' ' 13' ' ' CYS . 9.2 m -61.98 153.07 30.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.137 -176.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' 1' 1 ' 9' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -98.25 76.72 2.35 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.297 0.57 . . . . 0.0 109.483 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -70.65 3.1 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.231 -178.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.63 -23.89 0.5 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.981 -179.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 12' ' ' SER . . . . . . . . . . . . . 47.5 m -141.2 -177.94 5.35 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 122.634 -0.333 . . . . 0.0 110.158 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 13' ' ' CYS . . . . . 0.742 ' SG ' ' HA ' ' 1' ' 8' ' ' CYS . 72.7 m -131.43 25.04 4.81 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.093 0.473 . . . . 0.0 110.803 -178.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' 1' 1 ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.281 -178.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 15' ' ' SER . . . . . . . . . . . . . 20.4 m -70.78 -31.24 67.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.707 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 16' ' ' VAL . . . . . 0.475 ' O ' HG23 ' 1' ' 20' ' ' VAL . 77.5 t -62.4 -53.4 47.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.05 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' 1' 1 ' 17' ' ' CYS . . . . . . . . . . . . . 79.1 m -65.82 -29.98 70.54 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.918 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 18' ' ' ARG . . . . . . . . . . . . . 77.4 ttt180 -65.5 -31.37 72.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.147 0.499 . . . . 0.0 110.268 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 19' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -81.99 -40.16 22.57 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.719 177.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 20' ' ' VAL . . . . . 0.475 HG23 ' O ' ' 1' ' 16' ' ' VAL . 57.4 t -70.77 -70.28 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.535 -178.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' 1' 1 ' 21' ' ' ILE . . . . . . . . . . . . . 28.8 pt -100.21 -29.23 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 111.918 0.34 . . . . 0.0 111.918 -174.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.1 -37.03 2.37 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.072 -1.061 . . . . 0.0 113.378 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 23' ' ' VAL . . . . . . . . . . . . . 22.4 m -74.78 145.91 10.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 117.002 0.401 . . . . 0.0 110.673 -178.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 24' ' ' ALA . . . . . . . . . . . . . . . -95.64 40.65 1.11 Allowed 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.396 0.617 . . . . 0.0 110.484 -178.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 25' ' ' ALA . . . . . . . . . . . . . . . -119.18 106.77 12.69 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.518 175.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 26' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' 1' ' 34' ' ' VAL . . . -157.43 120.52 0.99 Allowed Glycine 0 N--CA 1.444 -0.826 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.305 -177.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' 1' 1 ' 27' ' ' LYS . . . . . . . . . . . . . 57.0 mtpt -111.17 159.07 18.21 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 120.983 0.42 . . . . 0.0 111.14 -174.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 28' ' ' CYS . . . . . . . . . . . . . 53.8 t -97.37 114.78 26.63 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.601 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 29' ' ' ILE . . . . . . . . . . . . . 69.9 mt -123.09 103.13 12.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.429 177.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 30' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 55.12 36.41 26.92 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.801 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 31' ' ' GLY . . . . . . . . . . . . . . . 83.59 22.3 56.38 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.347 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 32' ' ' ARG . . . . . 0.472 ' HD2' ' HA ' ' 1' ' 5' ' ' ASN . 36.6 mmt180 -124.28 156.21 37.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.699 0.285 . . . . 0.0 110.408 177.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' 1' 1 ' 33' ' ' CYS . . . . . . . . . . . . . 88.8 m -108.12 107.45 18.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.227 -177.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 34' ' ' VAL . . . . . 0.465 ' O ' ' HA2' ' 1' ' 26' ' ' GLY . 3.6 p -94.38 111.82 25.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.43 0.633 . . . . 0.0 110.233 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' 1' 1 ' 35' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.11 139.58 30.43 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 36' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -118.43 90.02 37.83 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.001 -178.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' 1' 1 ' 37' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo . . . . . 0 C--O 1.248 1.017 0 C-N-CA 122.641 2.227 . . . . 0.0 111.833 176.267 . . . . . . . . 0 0 . 1 stop_ save_